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Summary of the Major Research Project 
 
Section A is a narrative review, based on a systematic search of the literature, of case-
control studies exploring psychosocial associates of functional motor and sensory symptoms.  
Findings in the areas of depressive symptoms, anxiety symptoms, personality traits and 
pathology, precipitating life events, and childhood trauma are synthesized, and the 
methodological quality of the studies is evaluated.  The findings are discussed with reference 
to theoretical models and other relevant research, and recommendations for future research 
and clinical practice are made.   
 
Section B describes an empirical study investigating alexithymia and mentalization in 
functional neurological disorder (FND).  The differences between participants with FND and 
healthy control participants on a range of self-report measures were examined.  Significant 
between-group differences in alexithymia and hypomentalization were found.  Higher scores 
on measures of alexithymia and mentalization were also predictive of more somatic and 
neurological symptoms of a generalized nature, across all study participants.  Section B 
concludes with a consideration of limitations of the study, and a discussion of the research 
and clinical implications of the findings. 
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Abstract 
 
Theoretical models of functional neurological symptoms (FNS) have traditionally assumed 
that all of the symptoms have the same etiology, as they all resemble symptoms of 
neurological disorders.  Recent research has questioned whether symptoms that are acute and 
intermittent (e.g. functional seizures) may be different from those that are chronic and 
continuous (e.g. motor and sensory FNS).  This narrative review explored common 
psychosocial associates of motor and sensory FNS, based on a systematic literature search of 
case-control studies.  The Ovid MEDLINE and PsycINFO databases were searched in 
November 2017, along with reference lists from relevant papers, and 26 studies were 
retrieved.  Study quality was evaluated using the Downs and Black checklist for case-control 
studies.  Depressive symptoms, alexithymia, and precipitating life events/stressors were the 
most consistently reported associates of motor/sensory FNS, while the findings regarding 
anxiety, personality pathology, and childhood trauma were more mixed.  However, the 
sample sizes of reviewed studies were small, and FNS samples were predominantly drawn 
from specialist services, so the findings may not be generalizable.  The results offer some 
support for a theoretical model differentiating chronic and acute symptom presentations, and 
also raise questions about the usefulness of categorizing psychological phenomena using 
medical classification models.  
  
Keywords: Functional neurological symptoms, motor, sensory, psychosocial associates 
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A review of psychosocial associates of motor and sensory functional neurological symptoms 
Introduction 
Functional neurological symptoms (FNS) are ‘somatic symptoms which superficially 
resemble those of organic disorders of the nervous system, but for which no physical 
explanation can be found’ (Howlett, Grunewald, Khan, & Reuber, 2007, p. 354).  Common 
functional neurological symptoms include functional seizures (also known as psychogenic 
non-epileptic seizures or dissociative non-epileptic convulsions), sensory symptoms (such as 
numbness or loss of sensation) and motor symptoms (such as limb weakness or paralysis, gait 
disturbances, tremors, spasms or tics).   
The absence of identifiable organic pathology in FNS has led to greater attention 
being paid to possible psychological causes of the condition, resulting in FNS occupying a 
unique position at the intersection of several different clinical specialties, including 
neurology, neuropsychiatry, epileptology, occupational therapy, and psychology (McKee et 
al., 2018).  There remains, however, a lack of consensus regarding the mechanisms that 
underpin FNS (Carson et al., 2012).  Even the terms used to describe FNS have been the 
subject of debate and disagreement, with hysterical, dissociative, psychogenic, 
psychosomatic, somatoform, conversion and medically unexplained all used to describe the 
symptoms (and their putative origins) in different eras and contexts (Edwards, Stone, & 
Lang, 2014).  More recently, functional (indicating that the symptoms represent a change 
with the functioning, rather than the structure, of the brain) has become the preferred term, as 
it is relatively agnostic about the etiology of symptoms (Edwards, Stone and Lang, 2014), 
and it is the preferred term of service users and service user advocacy organisations (Stone et 
al., 2002; Rommelfanger et al., 2017).  This term, or FNS, is used throughout this paper. 
The lack of consensus regarding the nomenclature and classification of FNS may 
partly account for the variability in prevalence estimates of FNS, which range from 
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3.9/100,000 for functional weakness (Stone, Warlow & Sharpe, 2010), to 5/100,000 for 
functional motor symptoms (Binzer, Anderson, & Kullgren, 1997), and 1.4 – 33/100,000 for 
functional (non-epileptic) seizures (Reuber, 2008).  When all types of ‘conversion disorders’ 
are considered, prevalence rates of 50/100,000 cases known to health services at any one 
time, and twice that number over a one-year period, have been reported (Akagi & House, 
2002).  Individuals with FNS have levels of distress, disability and healthcare usage that are 
equal to, and often greater than, those of individuals with equivalent organic motor disorders 
(Carson et al., 2011), and the prognosis is often poor.  Reviewing prognostic studies with a 
mean weighted follow-up duration of 7.4 years, Gelauff, Stone, Edwards, and Carson (2014) 
found that more than one-third of those with functional motor symptoms had the same or 
worse symptoms at follow-up.  Durrant, Rickards, and Cavanna (2011) reported that fewer 
than 40% of those diagnosed with functional seizures as adults achieve seizure remission five 
years after diagnosis, compared to 60-80% of those diagnosed with epileptic seizures. 
 
Theoretical perspectives 
Historical and current theoretical models of FNS have typically encompassed all of 
the FNS symptom presentations, on the assumption that they are etiologically similar, as they 
all involve pseudoneurological symptoms inconsistent with their neuropathological 
equivalents (Kanaan, Duncan, Goldstein, Jankovic, & Cavanna, 2017). Early dissociation 
theories (e.g. Janet, 1889, 1907) proposed that functional symptoms arise from disturbances 
of the cognitive attentional system, caused by traumatic experiences.  Some symptoms (such 
as a loss of motor function or sensory anesthesia) develop when traumatic experiences lead to 
heightened attentional focus on some sensory channels, and other channels consequently 
being neglected.  This results in information from the neglected channels being processed 
outside of conscious awareness (i.e. in a dissociated fashion).  Other symptoms (such as 
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sensory distortions or functional seizures) occur when memories linked to traumatic 
experiences are not integrated in to the main autobiographical memory store, leading to a loss 
of conscious control over when they are activated or triggered by external/internal reminders 
of the memories (Roelofs & Spinhoven, 2007).     
Although Janet (1907) viewed dissociation as an abnormal response to traumatic 
experiences, seen in people with constitutional weakness (‘hysterics’), later neodissociation 
theories (e.g. Hilgard, 1977; Kihlstrom, 1992; Oakley, 1999) demonstrated that dissociation 
is a normal coping response to trauma, that becomes maladaptive when it is overgeneralized 
(Brown, 2004).  Other subsequent research on the impact of trauma on memory formation 
(e.g. van der Kolk, 1998) has offered further support for dissociation models.  However, the 
centrality of trauma in dissociation models is problematic, as many people with FNS do not 
report traumatic experiences prior to their symptom onset (e.g. Roelofs & Pasman, 2017)  
The conversion model of FNS (e.g. Breuer & Freud, 1893-1895/1982) had its origins 
in psychodynamic theory, and proposed that functional symptoms arise from the active 
repression by the ego of undesirable or emotionally painful thoughts, memories or emotions 
(Nemiah, 1989).  While this repression initially produces a ‘primary gain’ of protecting a 
person from painful experiences, preventing these memories from being ‘abreacted’ 
(discharged) in a normal way eventually leads to them being ‘converted’ into somatic 
symptoms, which were either present at the time of the trauma, or were symbolic 
representations of it (Roelofs & Spinhoven, 2007).  Freud originally believed that childhood 
sexual abuse was a key risk factor for the subsequent development of conversion as a defence 
mechanism,  though he modified this view in later revisions of the theory, emphasising 
instead the role of unconscious psychosexual conflict (Halberstadt-Freud, 1996).  Conversion 
models have been criticised due to the emphasis on unconscious processes making them 
unfalsifiable (Brown, 2004); however, the interest they generated in childhood abuse as a key 
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precipitant of FNS has been one of their enduring legacies (e.g. Roelofs, Keijsers, 
Hoogdumin, Näring, & Moene, 2002).   
Conversion models of FNS also introduced the concept that there may be ‘secondary 
gains’ to FNS, such as eliciting positive care and attention from others, or enabling 
unpleasant tasks (such as work or caring responsibilities) to be avoided (Roelofs & 
Spinhoven, 2007).  Secondary gains were a key area of interest in later social constructionist 
theories of FNS (Kozlowska, 2005) - Ruesch (1957) suggested that FNS may be an 
expression of emotions via ‘somatic language’, developmentally the earliest of three forms of 
human communication (succeeded by action and verbal language).  In this model, the 
function of a symptom, rather than its method of expression, is key to understanding its 
etiology – for some people, FNS may be a way of communicating distress, used as action or 
verbal language abilities are underdeveloped; for others, they may be an indirect, symbolic 
expression of conflict (interpersonal or situational) that a person cannot engage with directly; 
and for others, they may be an expression of physiological arousal in situations where fear or 
anxiety has overwhelmed the more sophisticated verbal language system. 
Interest in functional symptoms as expressions of emotional distress, rather than of 
repressed or converted trauma, also led Peter Sifneos (1973) to coin the term ‘alexithymia’ 
(from the Greek alexi, meaning ‘rebuff’, and thymos, meaning ‘emotions’) to describe a 
biological or developmental trait, characterized by difficulties in identifying and describing 
feelings, externally oriented thinking, and limited imaginal capacity (Taylor, 2000).  In the 
context of FNS, alexithymia has been proposed as a neurobiological mediator between 
emotional distress and physical symptoms, as well as an explanation as to why some people 
apparently remain oblivious to their emotional distress.  Although some early research 
findings regarding alexithymia and FNS appeared promising (e.g. Shipko, 1982), subsequent 
studies of groups of people with specific functional symptoms (e.g. functional seizures) have 
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suggested that rates of alexithymia are broadly comparable to those of people with other 
medical conditions (Brown & Reuber, 2016). 
The most recent theoretical models of FNS have focused on synthesizing elements of 
previous theories, using strengths of some models to compensate for shortcomings of others 
(Brown, 2004).  Richard Brown’s (2004) integrative conceptual model of medically 
unexplained symptoms, echoing dissociation theories, is underpinned by a cognitive 
attentional framework.  Drawing on Norman and Shallice’s (1986) dual attention model, it 
suggests that attention is controlled via two cognitive mechanisms: A primary attentional 
system (PAS), which controls routine actions in a way the feels intuitive and not requiring of 
conscious effort, as it utilises previously learned mental models (schemata); and a secondary 
attentional system (SAS), which is responsible for novel or complex actions, for which no 
mental model is already available, and as a result, feels more effortful and demanding of 
conscious control (Brown, 2004).  Functional symptoms characterized by alterations in 
experience (positive symptoms, such as pain, nausea, or pseudohallucinations) occur when 
inappropriate or inconsistent perceptual information is selected during the creation of 
schemata by the PAS; symptoms characterized by an inability to control perception, 
cognition, or action, arise when inappropriate cognitive mental models are automatically 
triggered during the process of schemata selection by the PAS.   
Drawing on conversion theories, Brown’s model includes a consideration of the 
impact of early life trauma, by explaining how increased body focus can act as a defense 
against the overwhelming affect or cognitions associated with trauma.  This accounts for why 
trauma is a common (though not a necessary) predisposing factor in FNS.  Elements of social 
constructionist theories are also incorporated, with the nature of the functional symptoms 
(e.g. seizures vs motor symptoms) explained as being partly influenced by a person’s 
exposure to similar symptoms in family/friends, or via sociocultural transmission.   
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Importantly, Brown’s model also proposes a mechanism to explain why symptoms 
may present in an acute or a chronic manner: for intermittent or time-limited phenomena 
(such as functional seizures), the automatic activation of a schema as an acute response to 
cues from the internal or external environment (e.g. fear or anxiety) is implicated; whereas 
for chronic motor or sensory symptoms, a chronic activation and selection of perceptual or 
behavioural schemata, is responsible (Brown, 2002). 
This element of Brown’s model, and the experiences of clinicians working with 
people with FNS, have led to increased questioning of the assumption of etiological 
equivalence of all functional symptoms, particularly in relation to functional seizures (e.g. 
Guz et al., 2003; Stone, Sharpe, & Binzer, 2004; Driver-Dunckley, Stonnington, Locke, & 
Noe, 2011).  Functional seizures tend to be intermittent and dramatic, accompanied by 
alterations of awareness, and often prompt medical intervention, including attempted 
resuscitation (Hopp, Anderson, Krumholz, Gruber-Baldini, & Shulman, 2012).  Motor and 
sensory symptoms, on the other hand, tend to be less dramatic, but are more likely to involve 
chronic and persistent symptoms, affecting everyday tasks (Ganos et al., 2014).  Based on a 
review of studies comparing characteristics of people with functional seizures to those of 
people with functional motor/sensory symptoms, Kanaan et al. (2017) proposed that different 
psychological mechanisms may be responsible for different functional symptom 
presentations: Acute symptoms (e.g. functional seizures) may be indicative of a 
developmental disorder, characterized by people dissociating in response to anxiety in 
situations which evoke the recall of earlier traumas; Chronic symptoms (e.g. functional 
motor/sensory symptoms), by contrast, may be an idiosyncratic yet adaptive coping response 
to recent stressful life events, as their consequence is often to draw in support from others.  
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Aim of this review 
Recent reviews of psychosocial risk factors of FNS (e.g. Brown & Reuber, 2016; 
Roelofs & Pasman, 2017) have focused primarily on studies of people with functional 
seizures.  However, if the model proposed by Kanaan et al. (2017) is valid, it is unclear if 
their findings would also apply to people with functional motor or sensory symptoms.  The 
aim of this review was therefore to explore common psychosocial associates of 
motor/sensory functional symptoms, via a systematic search for published case-control 
studies.  Based on the model proposed by Kanaan et al. (2017), it was hypothesized that 
functional motor/sensory symptoms would be associated with depressive symptoms and with 
stressful recent life events, as these functional symptoms reflect an impaired coping response 
to recent or current stressors.  Furthermore, functional motor/sensory symptoms would not 
show the same strength of association found in studies of people functional seizures (e.g. 
Brown & Reuber, 2016) with anxiety, childhood trauma, and personality pathology, as these 
associates are more indicative of a dissociative response to anxiety, with its origins in 
developmental trauma. 
Methods 
 
Search strategy 
Studies were first identified by searching the Ovid MEDLINE (1946 to present) and 
PsycINFO (1806 to present) electronic databases on 17 November, 2017, using search terms 
(listed in Table 1) related to functional motor and sensory symptoms, and to the associates of 
interest. The search was limited to English language papers only.  After removing duplicates, 
the titles and/or abstracts of the retrieved studies were screened to exclude studies that did not 
meet inclusion criteria for the review (such as book chapters, review articles or studies of 
other functional symptoms).  The full text of the remaining articles was read to determine 
whether the inclusion/exclusion criteria were met. 
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The inclusion criteria were: (i) empirical primary research studies; (ii) studies with a 
clinical sample of people with functional motor symptoms and/or functional sensory 
symptoms; (iii) studies with a control group(s) of healthy participants, participants with a 
psychiatric diagnosis, and/ or participants with an organic neurological disorder; (iv) studies 
that assessed relevant psychosocial associates by means of a validated self-report measure or 
a clinical interview (as a primary or secondary measure); and (v) studies of adults. As this 
was intended as a review of functional motor and sensory symptoms, studies where more 
than 10% of the functional symptoms sample had a primary diagnosis of functional seizures 
were excluded.  Studies that did not include a description of the symptom profile of the FNS 
sample, and studies of children/adolescents, were also excluded. 
Following the database search, additional studies were identified from the reference 
lists of included articles, with the same inclusion/exclusion criteria applied.  A PRISMA flow 
diagram (Liberati et al., 2009) of the search process is presented in Figure 1. 
 
Table 1. 
Database search query 
Search query 
 
#1 "functional neurologic*" or FND or FNSD or "conversion disorder" or 
"psychogenic neurologic*" or "non-organic neurologic* disorder" or 
"unexplained neurologic*" or "somatoform neurologic*" or "functional 
weakness" or "functional tremor" or "functional sensory" or "functional 
movement" or "functional dystonia" or "functional gait disturbance" or 
"functional speech" or "functional swallowing" or "psychogenic weakness" or 
"psychogenic tremor" or "psychogenic sensory" or "psychogenic movement" or 
"psychogenic dystonia" or "psychogenic gait disturbance" or "psychogenic 
speech" or "psychogenic swallowing" 
 
#2 "clinical characteristics" or "personality" or "psychopathology" or "depression" 
or "anxiety" or "panic" or "mental health" or "psychiatric" or "psychological" or 
trauma or stress or "life events" or "childhood adversity" or abuse or neglect 
 
#3 #1 AND #2 
 
Limit to English language. 
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Figure 1. PRISMA flow chart for literature search process 
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Assessment of quality 
The reviewed studies were evaluated using the 17 items relevant to case-control 
studies (Sanderson, Tatt & Higgins, 2007) of the Downs and Black (1998) checklist for 
assessing the methodological quality of randomised and non-randomised studies (Appendix 
1).  Checklist item 27 was simplified (as per MacLehose et al., 2000) to the question, “Was a 
power calculation reported for the primary outcome?”.  Checklist items were scored as 0 
(item criteria not fulfilled) or 1 (item criteria fulfilled), with the exception of item five 
(regarding confounding variables), which was scored as 0 (not fulfilled), 1 (partially fulfilled) 
or 2 (completely fulfilled).  Quality scores therefore ranged from 0-18.  As checklist items are 
not weighted by their relative risk to study quality (i.e. a lower score may not necessarily 
indicate lower study quality), the methodological quality of studies was also reviewed 
narratively. 
Results 
The search generated 24 papers, and two additional papers (Demartini et al., 2014; 
Fiess, Rockstroh, Schmidt, and Steffen, 2015) were identified from the references lists of 
included studies.  The studies’ locations, participants, measures and key findings are 
described in Table 2.  Several studies contained more than one control group, and the results 
of individual between-group comparisons are reported separately in the review.  The main 
results in each of the five areas of interest – depressive symptoms, anxiety symptoms, 
personality traits and pathology, precipitating life events/stressors, and childhood trauma – 
are presented first.  As many of the same methodological quality issues applied across the 
studies (and across the findings within them), these are then discussed in a separate section, 
with reference to specific findings, where applicable. 
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Table 2.  
Description and main findings of reviewed studies  
Study Clinical 
sample 
Control 
sample 
Location Depression 
measure and 
findings 
Anxiety 
measure and 
findings 
Personality 
measure and 
findings 
Life events 
measure and 
findings 
Trauma measure 
and findings 
Quality 
score 
Binzer, 
Andersen 
& Kullgren 
1(1997) 
30 participants 
with recent 
onset 
conversion 
disorder with 
motor 
symptoms 
30 participants 
with recent 
onset organic 
motor 
symptoms 
Umea and 
Kalmar, 
Sweden 
Structured 
Clinical 
Interview for 
DSM-IV Axis I 
disorders 
(SCID-I): 
Major 
depression† 
 
Hamilton 
Rating Scale 
for Depression 
(HRSD) 
(mean)*** 
Not assessed. Structured 
Clinical 
Interview for 
DSM-IV Axis II 
disorders (SCID-
II): Any 
personality 
disorder† 
5-item Life 
Events 
Inventory:  
Life events in 3 
months* before 
symptom onset 
(mean); 
Life events in 12 
months* before 
symptom onset 
(mean). 
Not assessed 11 
                                                        
Measures where a significant difference between the clinical sample and the control sample was reported are highlighted in bold.  
* Mean/median scores of clinical sample significantly higher than control sample, p ≤ 0.05; ** Mean/median scores of clinical sample 
significantly higher than control sample, p ≤ 0.01; *** Mean/median scores of clinical sample significantly higher than control sample, p ≤ 
0.001; † Diagnosis reported in significantly higher proportion of clinical sample than control sample, p ≤ 0.05; ^ Other significant difference(s) 
between clinical sample and control sample - see narrative review for further information. 
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Study Clinical 
sample 
Control 
sample 
Location Depression 
measure and 
findings 
Anxiety 
measure and 
findings 
Personality 
measure and 
findings 
Life events 
measure and 
findings 
Trauma measure 
and findings 
Quality 
score 
Binzer & 
Eisemann 
(1998) 
30 participants 
with recent 
onset 
conversion 
disorder with 
motor 
symptoms 
30 participants 
with recent 
onset organic 
motor 
symptoms 
Umea and 
Kalmar, 
Sweden 
Not assessed Not assessed SCID-II:  
Any personality 
disorder† 
 
N of interview 
criteria fulfilled 
for Cluster A* 
disorders,  
Cluster B* 
disorders,  
Cluster C 
disorders,  
and Global 
Index* (mean) 
Not assessed Egna Minnen 
Betreffande 
Uppfostran 
(EBMU) (Own 
memories of 
childrearing 
experiences)^ 
 
Clinical interview 
for self-reported 
childhood sexual 
abuse 
9 
Willinger 
& 
Aschauer 
(2005) 
61  
participants 
with 
functional 
dysphonia 
61 healthy 
control 
participants  
Vienna, 
Austria 
Beck 
Depression 
Inventory 
(BDI), German 
version 
(mean)* 
State-Trait 
Anxiety 
Inventory 
(STAI), German 
translation: 
STAI-State 
(mean) ns; 
STAI-Trait 
(mean)*. 
 
Interaction 
Anxiety 
Questionnaire: 
'Illness anxiety' 
factor (mean)*; 
'Anxiety of 
social situations' 
factor (mean) 
ns. 
Freiburg 
Personality 
Inventory: 
'Extraversion 
versus 
introversion' 
subscale (mean)* 
 
 
Not assessed Not assessed 12 
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Study Clinical 
sample 
Control 
sample 
Location Depression 
measure and 
findings 
Anxiety 
measure and 
findings 
Personality 
measure and 
findings 
Life events 
measure and 
findings 
Trauma measure 
and findings 
Quality 
score 
Seignourel 
et al. 
(2007) 
12 participants 
with 
psychogenic 
movement 
disorder 
(PMD) 
12 healthy 
control 
participants  
Florida, 
USA 
BDI (mean)** STAI - State 
(mean)** 
 
STAI - Trait 
(mean)** 
Not assessed Not assessed Not assessed 12 
Anderson 
et al. 
(2007) 
41 participants 
with 
psychogenic 
movement 
disorder 
(PMD) 
499 
participants 
with 
Parkinson's 
disease (PD) 
Maryland, 
USA 
Brief Symptom 
Inventory 
(BSI-18), 
depression 
scale 
(mean)*** 
Brief Symptom 
Inventory 
(BSI-18), 
anxiety scale 
(mean)*** 
Not assessed Not assessed Not assessed 11 
Espirito-
Santo & 
Pio-Abreu 
(2009) 
26 participants 
with DSM-IV 
conversion 
disorder 
(primarily 
motor and 
sensorial); 
39 participants 
with DSM-IV 
dissociative 
disorders; 
 
40 participants 
with DSM-IV 
somatization 
disorder; 
 
46 participants 
with other 
DSM-IV 
psychiatric 
disorders. 
Unspecified, 
Portugal 
BSI depression 
scale (mean) 
BSI anxiety, 
phobic anxiety 
and obsessive 
compulsive 
scales (mean) 
Not assessed Not assessed Not assessed 14 
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Study Clinical 
sample 
Control 
sample 
Location Depression 
measure and 
findings 
Anxiety 
measure and 
findings 
Personality 
measure and 
findings 
Life events 
measure and 
findings 
Trauma measure 
and findings 
Quality 
score 
Voon et al. 
(2010) 
16 participants 
with motor 
conversion 
disorder 
16 healthy 
control 
participants  
Bethesda, 
MD, USA 
(clinical 
sample); 
Unspecified 
USA 
(control 
sample) 
BDI (mean)*** Beck Anxiety 
Inventory 
(BAI) 
(mean)*** 
Not assessed Not assessed Not assessed 11 
Stone, 
Warlow & 
Sharpe 
(2010) 
107 
participants 
with 
functional 
weakness 
46 participants 
with weakness 
attributable to 
neurological 
disease 
South-East 
Scotland, 
UK 
SCID-I^ 
 
Hospital 
Anxiety and 
Depression 
Scale (HADS), 
Depression 
scale1: 
Scoring above 
clinical cut-
off†; 
Group median 
scores ns. 
SCID-I^ 
 
HADS anxiety 
scale¹:  
Scoring above 
clinical cut-off 
ns; 
Group median 
scores ns. 
Not assessed Not assessed Not assessed 15 
                                                        
1 Measures completed by 96/107 of the clinical sample and 40/46 of the control sample 
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Study Clinical 
sample 
Control 
sample 
Location Depression 
measure and 
findings 
Anxiety 
measure and 
findings 
Personality 
measure and 
findings 
Life events 
measure and 
findings 
Trauma measure 
and findings 
Quality 
score 
Kranick et 
al. (2011) 
64 participants 
with 
psychogenic 
movement 
disorder 
(PMD) cases 
39 participants 
with focal 
hand dystonia 
(FHD) 
controls; 
 
39 healthy 
control 
participants  
Bethesda, 
MD, USA 
(clinical and 
FHD 
samples); 
unspecified 
USA 
(healthy 
control 
sample) 
SCID-I (PMD 
and FHD groups 
only): Major 
depression 
(lifetime) ns. 
 
BDI (mean) 
*** 
SCID-I (PMD 
and FHD groups 
only): GAD, 
phobia and 
panic disorder 
ns. 
 
BAI (mean) 
*** 
Revised 
Neuroticism-
Extroversion-
Openness 
Personality 
Inventory (NEO 
PI-R) (PMD & HC 
groups only):  
Conscientious-
ness domain 
(mean)*;  
All other domains 
(means) ns. 
Social 
Readjustment 
Scale (PMD & 
FHD groups only) 
Childhood 
Trauma 
Questionnaire 
(CTQ)^ 
 
Traumatic Life 
Events 
Questionnaire 
(TLEQ)^ 
 
Parental Bonding 
Instrument 
(PBI)^ 
12 
Parees et 
al. (2012) 
18 participants 
with 
functional 
movement 
disorder 
(FMD) 
18 healthy 
control 
participants  
London, UK HADS 
depression 
scale (mean) 
*** 
HADS anxiety 
Scale 
(mean)*** 
Not assessed Not assessed Not assessed 11 
Voon et al. 
(2013) 
30 participants 
with 
psychogenic 
movement 
disorder and 
conversion 
disorder 
30 healthy 
control 
participants  
Bethesda, 
MD, USA 
(clinical 
sample); 
Unspecified 
USA 
(control 
sample) 
BDI (mean)*** BAI (mean)*** Not assessed Not assessed Not assessed 12 
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Study Clinical 
sample 
Control 
sample 
Location Depression 
measure and 
findings 
Anxiety 
measure and 
findings 
Personality 
measure and 
findings 
Life events 
measure and 
findings 
Trauma measure 
and findings 
Quality 
score 
DeMartini 
et al. 
(2014) 
55 participants 
with 
functional 
motor 
symptoms 
(FMS) 
33 participants 
with organic 
movement 
disorder 
(OMD) 
 
35 healthy 
controls 
London, UK Montgomery-
Asberg 
Depression 
Rating Scale 
(MADRS) 
(mean)** 
Not assessed SCID-II: OCPD†, 
all other PDs ns. 
 
Toronto 
Alexithymia 
Scale (TAS-20) 
(mean)** 
Not assessed Not assessed 11 
Brown, 
Nicholson, 
Aybek, 
Kanaan, & 
David 
(2014) 
21 participants 
with motor 
conversion 
disorder 
(inpatient and 
outpatient) 
36 healthy 
control 
participants  
South-East 
England, UK 
HADS 
depression 
scale (mean)* 
HADS anxiety 
scale (mean)* 
Not assessed Not assessed Not assessed 11 
Aybek et 
al. (2014) 
12 participants 
with DSM-IV 
sensory / 
motor 
conversion 
disorder 
13 healthy 
control 
participants  
South-East 
London, UK 
HADS 
depression 
scale (mean)* 
HADS anxiety 
scale (mean) 
Not assessed Not assessed Not assessed 12 
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Study Clinical 
sample 
Control 
sample 
Location Depression 
measure and 
findings 
Anxiety 
measure and 
findings 
Personality 
measure and 
findings 
Life events 
measure and 
findings 
Trauma measure 
and findings 
Quality 
score 
van der 
Hoeven et 
al. (2015) 
55 participants 
with 
functional 
movement 
disorder 
(FMD) 
34 participants 
with organic 
movement 
disorder 
(OMD) 
 
52 healthy 
control 
participants  
Groningen, 
The 
Netherlands 
Not assessed Not assessed Personality 
Diagnostic 
Questionnaire 
(PDQ-4) 
Not assessed Not assessed 13 
Fiess, 
Rockstroh, 
Schmidt, & 
Steffen 
(2015) 
20 participants 
with ICD-10 
cases with 
ICD-10 
dissociative 
disorders 
(motor, 
sensory, or 
mixed 
excluding 
functional 
seizures;) 
20 healthy 
control 
participants  
Konstanz, 
Germany 
Not assessed Not assessed Toronto 
Alexithymia 
Scale, German 
version (TAS-26) 
(median)*** 
Not assessed Not assessed 12 
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Study Clinical 
sample 
Control 
sample 
Location Depression 
measure and 
findings 
Anxiety 
measure and 
findings 
Personality 
measure and 
findings 
Life events 
measure and 
findings 
Trauma measure 
and findings 
Quality 
score 
Steffen, 
Fiess, 
Schmidt & 
Rockstroh 
(2015) 
45 participants 
with motor 
and/or 
sensitivity 
dissociative 
disorders 
45 healthy 
control 
participants  
Konstanz, 
Germany 
Not assessed. Not assessed. TAS-26 
(mean)*** 
 
Life Events 
Questionnaire 
(LEQ):  
Negative life 
events in last 12 
months 
(mean)***;  
Positive life events 
in last 12 months 
(mean) ns. 
Early Trauma 
Inventory, German 
version (ETI) (all 
median scores):  
General 
trauma**; 
Emotional 
trauma***; 
Physical trauma 
ns; 
Sexual abuse ns. 
12 
Aybek et 
al. (2015) 
12  
participants 
with DSM-IV 
motor 
conversion 
disorder 
14 healthy 
control 
participants  
South-East 
London, UK 
HADS 
depression 
scale:  
Scoring above 
clinical cut-
off†; 
Group mean 
scores ns. 
HADS anxiety 
scale: 
Scoring above 
clinical cut-off 
ns; 
Group mean 
scores ns. 
Not assessed Not assessed Clinical interview 
for self-reported 
history of sexual 
abuse 
12 
Maurer et 
al. (2016a) 
35 participants 
with 
functional 
movement 
disorder 
(FMD) 
35 healthy 
control 
participants  
Bethesda, 
MD, USA 
(clinical 
sample);  
 
Unspecified 
USA 
(control 
sample) 
HRSD 
(mean)*** 
 
BDI (mean)*** 
Hamilton 
Rating Scale 
for Anxiety 
(HAM-A) 
(mean)*** 
Not assessed Not assessed CTQ (all scales) 11 
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Study Clinical 
sample 
Control 
sample 
Location Depression 
measure and 
findings 
Anxiety 
measure and 
findings 
Personality 
measure and 
findings 
Life events 
measure and 
findings 
Trauma measure 
and findings 
Quality 
score 
Maurer et 
al. (2016b) 
35 participants 
with 
functional 
movement 
disorder 
(FMD) 
38 healthy 
control 
participants  
Bethesda, 
MD, USA 
(clinical 
sample);  
 
Unspecified 
USA 
(control 
sample) 
HRSD 
(mean)*** 
 
BDI (mean)** 
HAM-A 
(mean)*** 
Not assessed Not assessed Not assessed 11 
Fiess, 
Rockstroh, 
Schmidt, 
Wienbruch, 
& Steffen 
(2016) 
21 participants 
with ICD-10 
dissociative 
disorders 
(motor, 
sensory, or 
mixed 
excluding 
functional 
seizures;) 
21 healthy 
control 
participants  
Konstanz, 
Germany 
Symptom 
Check List 
Revised, 
German 
version (SCL-
R-90): 
Depression 
scale 
(median)*** 
Not assessed Not assessed Not assessed ETI, German 
version 
(median)*** 
12 
Nicholson 
et al. 
(2016) 
43 participants 
with motor 
conversion 
disorder 
28participants  
with 
psychiatric 
diagnosis 
(depression) 
 
28 healthy 
control 
participants  
London, UK (Cases vs HC) 
HADS 
depression 
scale (mean)* 
(Cases vs HC) 
HADS anxiety 
scale (mean) 
Not assessed Life Events and 
Difficulties Scale 
(LEDS)^ 
Clinical 
interview^ 
10 
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Study Clinical 
sample 
Control 
sample 
Location Depression 
measure and 
findings 
Anxiety 
measure and 
findings 
Personality 
measure and 
findings 
Life events 
measure and 
findings 
Trauma measure 
and findings 
Quality 
score 
Tomic et 
al. (2017) 
39 participants 
with 
functional 
dystonia 
(DysF) 
30 participants 
with 
idiopathic 
(primary) 
dystonia 
(DysP) 
Belgrade, 
Serbia 
HRSD (mean) 
 
Psychiatric 
interview^ 
HAM-A (mean) 
 
Psychiatric 
interview 
NEO PI-R (all 
mean scores): 
Extraversion*; 
Openness to 
experience*; 
All other domains 
ns. 
 
Psychiatric 
interview 
Psychiatric 
interview: 
presence of 
stressor before 
onset of 
symptoms† 
Not assessed 10 
Apazoglou, 
Mazzola, 
Wegrzyk, 
Polara & 
Aybek 
(2017) 
16 participants  
with motor 
functional 
neurological 
disorder 
(motor FND) 
15 healthy 
control 
participants  
Geneva, 
Switzerland 
BDI (mean)* STAI - State 
scale (mean) 
 
STAI - Trait 
scale (mean) 
Not assessed Amiel-Lebigre 
questionnaire:  
N of sig. life 
events (last 5 yrs) 
(mean) 
Impact of sig. life 
events (last 5 yrs) 
(mean) 
CTQ (mean scale 
scores): 
Sexual abuse*;  
all other domains 
ns. 
10 
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Study Clinical 
sample 
Control 
sample 
Location Depression 
measure and 
findings 
Anxiety 
measure and 
findings 
Personality 
measure and 
findings 
Life events 
measure and 
findings 
Trauma measure 
and findings 
Quality 
score 
Kienle et 
al. (2017) 
60 participants 
with ICD-10 
dissociative 
disorders 
(motor, 
sensory, or 
mixed 
excluding 
functional 
seizures) 
39 participants 
with diagnosis 
of PTSD 
 
40 healthy 
control 
participants  
Konstanz & 
Gailingen, 
Germany 
(clinical 
sample); 
Mannheim, 
Germany 
(PTSD 
control 
sample); 
unspecified 
Germany 
(healthy 
control 
sample) 
Not assessed Not assessed TAS-26 
(median)*** 
Not assessed Post-traumatic 
Stress Diagnostic 
Scale (PDS)^ 
 
German version 
of Maltreatment 
and Abuse 
Chronology of 
Exposure 
(KERF)^ 
12 
Ekanayake 
et al. 
(2017) 
59 participants 
with 
psychogenic 
movement 
disorder 
26 healthy 
control 
participants  
 
(43 control 
participants 
with 
psychogenic 
non-epileptic 
seizures) 
Maryland, 
USA 
(clinical 
sample); 
unspecified 
USA 
(control 
sample) 
BDI-II 
(mean)** 
Not assessed. NEO PI-R: All 
five domains ns. 
 
Neuroticism 
facet of 
'Depression'* 
Not assessed CTQ (mean scale 
scores):  
Emotional 
abuse*;  
all other domains 
ns. 
 
TLEQ: Age when 
experienced most 
traumatic event. 
12 
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Depressive symptoms 
Of the 26 reviewed studies, 21 assessed depressive symptomology. Sixteen studies 
compared groups of participants with functional motor/sensory symptoms to healthy control 
participants, using validated self-report measures, including the Beck Depression Inventory 
(BDI; Beck & Steer, 1987; Beck, Steer, & Brown, 1996), the depression scale of the Hospital 
Anxiety and Depression Scale (HADS; Zigmond & Snaith, 1983), the Hamilton Rating Scale 
for Depression (HRSD; Hamilton, 1960), the depression subscale of the Brief Symptom 
Inventory (BSI; Zabora et al., 2001), the Montgomery-Asberg Depression Rating Scale 
(MADRS; Davidson, Turnbull, Strickland, Miller, & Graves, 1986), and the Symptom Check 
List Revised (SCL-R-90; Derogitas & Unger, 2010).  Fifteen (94%) of these studies found 
that the mean or median depression scores of the functional symptoms sample were 
significantly higher than those of healthy controls.  One study (Aybek et al., 2015) did not 
find a significant difference in mean/median scores, but it did find that a significantly greater 
proportion of the functional symptoms sample scored above the established measure 
threshold for a diagnosis of ‘clinical depression’. 
Six studies made comparisons to control samples of people with organic neurological 
disorders, and four (67%) reported significantly higher scores in the functional symptoms 
sample on self-report measures of depressive symptoms.  A fifth study (Tomic et al., 2017) 
also reported higher mean scores, but the difference was just short of statistical significance 
(p = 0.072).  The sixth study (Stone, Warlow, & Sharp, 2010) did not find a significant 
difference in median scores, but did find that a significantly higher proportion of the 
functional symptoms sample scored above the clinical threshold for ‘caseness’. 
Four of the six studies with organic disorder control samples also assessed on 
categorical depression diagnoses.  Three studies used the clinician-rated Structured Clinical 
Interview for DSM-IV Axis I disorders (SCID-I; First, Spitzer, Gibbon, & Williams, 1995).  
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Binzer et al. (1997) found that a significantly higher proportion of their functional symptoms 
sample met criteria for a current major depressive episode (corresponding with the findings 
from their self-report measure). Stone et al. (2010) also found that a significantly higher 
proportion of their functional weakness sample met the diagnostic criteria for a current major 
depressive disorder (corresponding with their findings regarding ‘caseness’, but not median 
scores, on a self-report measure).  Kranick et al. (2011) found no significant between-group 
differences in categorical diagnoses of depression in their sample (contrasting with the 
finding of their self-report measure).  The fourth study, Tomic et al. (2017) used a psychiatric 
interview to assess categorical diagnoses – they found that a significantly higher proportion 
of the functional symptoms sample had experienced a major depressive episode prior to 
developing functional symptoms, and also that a higher proportion of the functional 
symptoms sample met criteria for a current diagnosis of recurrent major depressive disorder, 
though this difference was marginally below statistical significance (19.4% vs 3.3%; 
p=0.063).  There were no significant between-group differences on prior dysthymia, current 
major depressive episode, or current dysthymia, diagnoses. 
Espirito-Santo and Pio-Abreu (2009) was the only reviewed study to evaluate 
depressive symptomology with control groups of people with other psychiatric diagnoses.  
They found no significant between-group differences in mean scores on the self-report BSI 
depression scale. 
In summary, of the 21 studies that included a measure of depression, 16 (76%) found 
evidence of significantly higher depressive symptomology in the functional symptoms 
sample than in matched control groups (13/14 studies with healthy control samples, 2/4 
studies with organic disorder control samples, and 1/2 studies with healthy and organic 
disorder control samples).  Four (19%) of the reviewed studies (1/14 studies with healthy 
controls samples, 2/4 studies with organic disorders control samples, and 1/2 studies with 
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healthy and organic disorder control samples) reported a divergence in findings between 
multiple measures, with a least one measure finding significant differences, and one measure 
finding no significant differences.  The study with a control group of participants with 
psychiatric disorder diagnoses was the only reviewed study that did not find any evidence of 
significantly higher depressive symptomology in the functional symptoms sample. 
 
Anxiety symptoms 
Seventeen of the reviewed studies assessed anxiety symptoms.  Thirteen studies 
compared aspects of anxiety between functional symptoms samples and healthy control 
samples.  Ten of these studies used a global self-report measure of anxiety, such as the 
anxiety subscale of the HADS (Zigmond & Snaith, 1983), the Hamilton Anxiety Rating Scale 
(HARS; Hamilton, 1959) or the Beck Anxiety Inventory (BAI; Beck, Epstein, Brown, & 
Steer, 1988).  Seven (70%) of the ten studies found significantly higher mean or median 
anxiety scores in the functional symptoms samples, with the remaining three studies finding 
no significant differences.  
The other three studies with healthy control samples used the State-Trait Anxiety 
Inventory (STAI; Spielberger, Gorusch, & Lushene, 1970), which assesses anxiety as a 
reactive state (state anxiety), and as a stable personality characteristic (trait anxiety).  These 
studies reported conflicting findings: Apazoglou, Mazzola, Wegrzyk, Polara and Aybek 
(2017) found no significant between-group differences on state or trait anxiety; Seignourel et 
al. (2007) found the functional symptoms sample had significantly higher mean scores on 
both the state and the trait scales; while Willinger and Aschauer (2005) found the functional 
symptoms sample had significantly higher mean scores on the trait scale, but not on the state 
scale.  Willinger and Aschauer (2005) also found that their functional dysphonia sample had 
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significantly higher scores on the illness anxiety scale, but not on the social anxiety scale, of 
the Interaction-Anxiety Questionnaire (Becker, 1997).     
Four studies made comparisons to control samples of people organic disorders using 
self-report measures – two of these studies found significantly higher mean/median anxiety 
scores in the functional symptoms samples, and two studies found no significant differences.  
Three of these studies also used clinician-rated categorical measure of anxiety, again 
reporting mixed results.  Using the SCID-I, Stone et al. (2010) found that a significantly 
higher proportion of their functional weakness sample met the diagnostic criteria for panic 
disorder, somatization disorder and generalized anxiety disorder, but no significant between-
group differences on agoraphobia, hypochondriasis, OCD or social phobia.  Using the same 
measure, Kranick et al. (2011) found no significant between-group differences on diagnoses 
of generalized anxiety disorder, phobias, or panic disorder.  Tomic et al. (2017) used a 
psychiatric interview to evaluate categorical anxiety diagnoses, and also found no significant 
between-group differences. 
Espirito-Santo & Pio-Abreu (2009) was the only study to explore anxiety in control 
samples with psychiatric disorder diagnoses.  They found no significant between-groups 
differences on the anxiety scale of the BSI.   
In summary, of the 17 studies that assessed anxiety, eight studies (47%) found 
evidence of significantly higher anxiety in groups of people with functional symptoms than in 
control groups (7/12 studies with healthy control groups, and 1/3 studies with organic 
disorders control groups); six studies (35%) found no evidence of significantly higher anxiety 
in functional symptoms samples compared to control groups (4/12 studies with healthy 
control groups, 1/3 studies with organic disorders control groups, and the one study with 
control groups of people with psychiatric diagnoses); and the remaining three studies (18%) 
reported different findings according to different measures (1/12 studies with healthy control 
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groups, 1/3 studies with organic disorders control groups, and the one study with healthy 
control and organic disorders control groups).   
 
Personality traits and pathology 
Eleven of the reviewed studies assessed aspects of personality.  Four studies assessed 
personality disorder diagnoses.  As assessed by the clinician-rated Structured Clinical 
Interview for the DSM-IV Axis II disorders (SCID-II; First, Spitzer, Gibbons, Williams, & 
Benjamin, 1996), Binzer et al. (1997) found that a significantly higher proportion of the 
functional symptoms sample met the criteria for a personality disorder diagnosis, though 
there were no significant group differences on any specific personality disorder diagnoses.  In 
subsequent analyses of the same data, Binzer and Eisemann (1998) reported that the 
functional symptoms sample met significantly more of the interview criteria for Cluster A 
(odd, bizarre or eccentric) and Cluster B (dramatic, erratic) disorders, but not Cluster C 
(anxious, fearful) disorders, than the organic disorders sample.  
These findings regarding personality psychopathology were not replicated in other 
studies, however.  DeMartini et al. (2014), using the SCID-II with samples with functional 
symptoms, organic motor disorders, and healthy controls, found no significant between-group 
differences on any personality disorder, with the exception of a significantly higher 
proportion of the functional symptoms sample meeting criteria for obsessive-compulsive 
personality disorder (OCPD), a Cluster C disorder.  van der Hoeven et al. (2015) used a self-
report measure, the Personality Diagnostic Questionnaire (PDQ-4; Hyler, Skodol, Kellman, 
Oldham, & Rosnick, 1990), and found no significant differences between the proportions of 
the samples with functional symptoms, organic disorders, and healthy control participants, 
scoring above the clinical cut-off for personality pathology.  Tomic et al. (2017) also found 
no significant differences between their samples with functional dystonia and organic 
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dystonia, on diagnoses of histrionic, borderline, or undifferentiated personality disorders (as 
assessed by psychiatric interview).  
Three of the reviewed studies assessed personality using the Neuroticism-
Extroversion-Openness Personality Inventory Revised (NEO PI-R; Costa & McCrae, 1985), 
a self-report measure of five dimensional domains (Neuroticism, Conscientiousness, 
Extraversion, Agreeableness and Openness).  There were no consistent findings across these 
studies: Kranick et al. (2011) found that a functional symptoms sample had significantly 
lower mean scores than a healthy controls sample on the Conscientiousness domain, but no 
significant differences on the other four domains; Ekanyake et al. (2017) found no significant 
differences between a functional symptoms sample and a healthy controls sample on any of 
the five domains; and Tomic et al. (2017) found that a functional symptoms sample had 
significantly lower scores than an organic disorders control sample on the ‘Extroversion’ and 
‘Openness’ domains, but not on the other domains.  Willinger and Aschauer (2005) also 
assessed extroversion as a dimensional aspect of personality, using “extraversion versus 
introversion” scale of the Freiburg Personality Inventory (Fahrenberg, Hampel, & Selg, 
1994).  They found that a functional symptoms sample had significantly lower levels of 
extroversion, than a healthy controls sample.   
Four of the reviewed studies assessed alexithymia using the Toronto Alexithymia 
Scale (TAS-20; Bagby, Taylor, & Parker, 1994) or the German version of the scale, the TAS-
26 (Kupfer, Brosig, & Brähler, 2001).  Each of the three studies that compared samples with 
functional symptoms to healthy control samples found that the functional symptoms samples 
had significantly higher mean/median alexithymia scores, as did the study that made 
comparisons to an organic disorders control sample.  Kienle et al. (2017) also compared the 
TAS-26 scores of a functional symptoms sample to a sample of people diagnosed with post-
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traumatic stress disorder (PTSD) – they found that the functional symptoms sample had 
significantly lower median alexithymia scores.   
In summary, one of the reviewed studies found significantly higher rates of 
personality disorder diagnoses in a functional symptoms sample, when compared to an 
organic disorders control sample, but two studies (one with an organic disorders control 
sample, and one with healthy and organic disorders control samples) found no significant 
differences.  A fourth study, also with healthy control and organic disorders control samples, 
found significantly higher rates of obsessive-compulsive personality disorder diagnoses in the 
functional symptoms sample, but not other personality disorder diagnoses.  There did not 
appear to be any consistent findings across the four reviewed studies that used dimensional 
measures of personality.  On the other hand, all of the reviewed studies that assessed 
alexithymia found evidence of significantly higher alexithymic traits in people with 
functional symptoms (three studies with healthy control groups, and one study with an 
organic disorders control group), with the exception of one study that made comparisons to a 
control group of participants with PTSD. 
 
Precipitating life events/stressors 
 
Six of the reviewed studies included a measure of significant recent life events / 
stressors.  Three of these studies made comparisons to samples of healthy controls 
participants. Steffen et al. (2015) found that the functional symptoms sample had experienced 
significantly more negative life events, but not positive life events, in the preceding 12 
months, as assessed by the Life Events Questionnaire (LEQ; Norbeck, 1984).  Negative life 
events were also a significant predictor of the severity of functional symptoms in a multiple 
logistic regression model.  Nicholson et al. (2016) found that people with functional 
symptoms were significantly more likely to have experienced at least one severe life event in 
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the month before symptom onset, and/or at least one stressor where the development of 
functional symptoms would have secondary gains (i.e. would enable ‘escape’ from a 
stressor), as assessed by clinician-rated Life Events and Difficulties Schedule (LEDS; Brown 
and Harris, 1989).  The mean number of severe events, and those linked to potential 
secondary gains, in the month preceding symptom onset, was also significantly higher in the 
functional symptoms sample.  Apazoglu et al. (2017) found no significant between-group 
differences in the number of significant life events, and the subjective impact of those life 
events, in the preceding five years, as assessed by the Amiel-Lebigre questionnaire (Cottraux, 
Bouvard, & Légeron, 1985).  
Three studies explored precipitating life events with control samples of people with 
organic disorders. Binzer et al. (1997), using an unvalidated measure (Perris, 1984) of 
significant life events in five areas (work, family life, economy, illness or death amongst 
family/friends, and personal illness), found that the functional symptoms sample reported a 
significantly higher mean number of significant life events in the 4-month and 12-month 
periods prior to symptom onset.  As assessed by psychiatric interview, Tomic et al. (2017) 
found that a functional symptoms sample had significantly more frequent stressors preceding 
the onset of their symptoms.  Experiencing stress before symptom onset also independently 
predicted having functional (versus organic) symptoms, in a binary logistic model.  Kranick 
et al. (2011), however, found no significant between-group differences in number of stressors 
(and their impact) in the year prior to symptom onset, as assessed by the Social Readjustment 
Scale (Holmes & Rahe, 1967). 
Finally, Nicholson et al. (2016) explored precipitating life events in a functional 
symptoms sample, and a control sample of people with a diagnosis of depression, using the 
LEDS.  They found that people with functional symptoms were significantly more likely than 
people with a diagnosis of depression to have experienced at least one severe life event in the 
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month before symptom onset, and/or at least one stressor where the development of 
functional symptoms would have secondary gains.  They also found that the mean number of 
severe events, and of events linked to potential secondary gains, in this month was 
significantly higher in the functional symptoms sample. 
In summary, five of the seven studies (2/3 studies with healthy control samples, 2/3 
studies with organic disorders control samples, and the one study with a control group of 
people with depression) found evidence of higher rates of significant life events / stressors 
preceding symptom onset in people with functional symptoms, than in control group 
participants. 
 
Trauma history 
Ten of the reviewed studies (with nine healthy control samples, two organic disorders 
control samples, and two psychiatric disorders control samples) assessed trauma history 
(childhood and/or lifetime), using clinician interview or validated self-report measures, such 
as the Childhood Trauma Questionnaire (CTQ; Bernstein & Fink, 1998), the Early Trauma 
Inventory (ETI; Wingenfeld et al., 2011), the Maltreatment and Abuse Chronology of 
Exposure scale (KERF; Isele et al., 2014), or the Traumatic Life Events Questionnaire 
(TLEQ; Kubany et al., 2000).  As many of these measures assess trauma across similar 
domains (sexual abuse, physical abuse/neglect, and emotional abuse/neglect), the key 
findings are summarised in Table 3. 
There were also some other findings of note regarding trauma.  Although no 
significant between-group differences in sexual abuse were found by Steffen et al. (2015), 
they did find that individuals with multiple functional symptoms significantly more 
frequently reported sexual abuse, compared to those with single-domain functional 
symptoms.  
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Several studies also included measures of trauma across the lifespan.  In addition to 
their findings regarding childhood trauma, Kienle et al. (2017) found that their functional 
symptoms sample had experienced more traumatic events across their lifetime than healthy 
control participants, as assessed by the PDS.  Two studies used elements of the Traumatic 
Life Events Questionnaire (TLEQ; Kubany et al., 2000): Kranick et al. (2011) found that a 
functional symptoms sample reported a significantly more lifetime traumatic episodes, and 
significantly greater fear associated with traumatic events, than control groups of healthy 
participants or participants with organic disorders.  The functional symptoms sample also 
reported a significantly greater number of traumatic events than people in the control groups 
(though this difference was no longer significant after correcting for multiple comparisons).  
Ekanyake et al. (2017) used the item from the TLEQ regarding the timing of the most 
traumatic event occurring – they found no significant differences between a functional 
symptoms sample and a healthy controls sample on the mean age at which people 
experienced their most traumatic event.  
Finally, two studies looked at memories of parenting experiences in their samples. 
Binzer and Eisemann (1998) found that participants with functional symptoms recalled 
significantly less emotional warmth, and significantly more rejection, from both parents, than 
control participants with organic disorders, as assessed by the self-report Own Memories of 
Childrearing Experiences questionnaire (Perris, Jacobsson, Linndström, Knorring, & Perris, 
1980).  Kranick et al. (2011), using the Parental Bonding Inventory (Parker, Tupling, & 
Brown, 1979), also found that a functional symptoms sample reported significantly lower 
perceived paternal and maternal parental care than control groups of healthy participants and 
participants with organic disorders (though the differences no longer met the level of 
statistical significance after correcting for multiple comparisons).  Neither of these studies 
found significant between-group differences on experiences of parental overprotection.   
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In summary, eight (80%) of the 10 studies that assessed childhood trauma found some 
evidence of higher rates of childhood trauma in functional symptoms samples than in control 
samples (4/6 studies with healthy control groups, both of the studies with healthy and 
psychiatric diagnosis control groups, the one study with healthy and organic disorders control 
groups, and the one study with a control group of people with organic disorders).  However, 
there was little consensus amongst the studies on which types of childhood trauma were most 
common, though emotional abuse was more commonly reported than sexual or physical 
abuse. 
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Table 3.  
Summary of findings regarding childhood traumas  
      Significantly higher rates reported in functional symptoms sample? 
 
  
Control group 
participants Measure 
Sexual 
abuse 
Physical 
abuse 
Physical 
neglect 
Emotional 
abuse 
Emotional 
neglect 
Overall 
childhood 
adversity 
Kranick et al. (2011) Healthy CTQ No Yes1 Yes Yes No N/A 
Aybek et al. (2015) Healthy Clinical interview No N/A N/A N/A N/A N/A 
Steffen et al. (2015) Healthy ETI No Yes Yes Yes 
Fiess et al. (2016) Healthy ETI N/A N/A N/A N/A N/A Yes 
Maurer et al. (2016) Healthy CTQ No No No No No N/A 
Nicholson et al. (2016) Healthy Clinical interview Yes No N/A N/A N/A N/A 
Apazoglou et al. (2017) Healthy CTQ Yes No No No No N/A 
Ekanayake et al. (2017) Healthy CTQ No No No Yes No N/A 
Kienle et al. (2017) Healthy KERF No Yes Yes N/A 
Binzer & Eisemann (1998) Organic disorders Clinical interview No N/A N/A N/A N/A N/A 
Kranick et al. (2011) Organic disorders CTQ No 
Yes1 
Yes Yes No N/A 
Nicholson et al. (2016) Psychiatric disorders 
(depression)2 
Clinical interview No No N/A N/A N/A N/A 
Kienle et al. (2017) Psychiatric disorders 
(PTSD) 
KERF No No No No No No 
         
 Total number of 
significant findings 
 2/12 4/10 4/10 5/8 2/8 2/3 
                                                        
1 Difference no longer statistically significant after controlling for multiple comparisons 
2 Female participants only. 
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Assessment of quality 
The quality of the reviewed studies was moderate, with study quality scores on the 
Downs and Black (1998) checklist ranging from 7-15 (mean 11.4).  Further details of the 
quality assessment scoring are provided in Table 4.   
A number of general and specific methodological issues warrant consideration. 
Firstly, none of the studies fully met the evaluation criteria regarding the representativeness 
of the samples, as all of the functional symptoms samples were recruited from specialist 
services (such as inpatient or outpatient neurology services, neurological rehabilitation 
services, or neuropsychiatry services).  Many individuals with functional symptoms will be 
referred on to specialist services, but people with acute and/or transient symptoms, more 
likely to be seen in primary care, by community mental health teams, or not at all (Akagi and 
House, 2002), may be underrepresented in this research.   
Secondly, sample sizes of the groups of participants with functional symptoms tended 
to be small (M = 37, Mdn = 32.5).  Based on Cohen’s (1992) widely-used criteria, none of the 
studies had sufficient power to detect small or medium effects, 17 (65%) studies had 
adequate power to detect large effects only, and the remaining nine studies were only 
powered to detect very large effects.  Although small sample sizes are not unexpected due to 
the relatively low incidence of functional symptoms, there is an increased risk of Type II 
errors, due to studies being underpowered.  Many of the studies also did not control for 
making multiple comparisons (increasing the risk of Type I errors).  When such corrections 
were made, some significant findings were no longer statistically significant. 
Thirdly, several of the reviewed studies included in the review also took place at the 
same research centres (see ‘Location’ column in Table 2).  Findings do not appear to have 
been reported repeatedly across multiple studies, but the possible use of the same samples in 
multiple studies is a potential confounder of the findings of this review. 
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With regards to the findings regarding depressive symptoms, many of the reviewed 
studies excluded participants with a diagnosis of depression from their healthy control 
groups.  As a result, depressive symptoms may have been less common in these control 
groups than would normally be found in the general population.  However, the findings from 
these studies were broadly consistent with studies that did not exclude control group 
participants on this basis.  Furthermore, Voon et al. (2013) excluded participants with current 
major depression of moderate severity from the functional symptoms sample, and still found 
that the functional symptoms sample had significantly higher mean BDI scores than the 
healthy controls sample. 
Regarding the findings on personality disorders, the only study (Binzer and Eisemann, 
1998) to find significantly higher rates of personality disorder diagnoses in a functional 
symptoms sample was also the only study to use exclusively in-patient participants.  In order 
to reach a threshold for inpatient admission, these participants may have had more severe 
difficulties than average, and none of the other studies that measured personality 
psychopathology reported a prevalence rate even near the 50% reported in this sample.  The 
functional symptoms sample also had significantly lower educational attainment than control 
participants, which may have been another significant confounding factor, as there is 
evidence that lower educational attainment is a predictor of personality disorder diagnoses 
(e.g. Huang et al., 2009).  
A number of other methodological issues are also worth noting.  The use of 
unvalidated measures, particularly clinical interviews, may have affected the reliability of 
some of the reported study results.  There have also been queries raised regarding the validity 
and reliability of retrospective self-reports of trauma histories (Hardt & Rutter, 2004). 
However, the use of the same measures with the clinical and control groups negates the 
impact of these limitations somewhat.  In addition, although studies that assessed depressive 
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and anxiety symptoms utilized the same measures with the clinical and control groups, there 
is a risk that between-group differences may have arisen from spurious associations between 
measure items assessing physical symptoms of depression/anxiety, and the physical 
manifestations of the functional motor/sensory symptoms themselves.  Additional factor 
analyses of the types of depressive/anxiety symptoms being reported may be valuable in 
exploring this issue further.   
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Table 4. 
Evaluation of methodological quality of the reviewed studies, based on Downs and Black (1998) checklist 
Study Downs and Black Checklist Item Total Notes 
 
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27* 
(max. 
18) 
 Binzer, 
Andersen & 
Kullgren 
(1997) 
1 1 1  2 1 1   0 0 0   0 0  1  0 1 1   0  0 
10 
* Unvalidated Life Events Inventory used 
* Hypotheses not stated in introduction 
* Cases were all inpatients 
Binzer & 
Eisemann 
(1998) 
0 1 1  2 1 1   0 0 0   0 0  1  0 0 0   0  0 
7 
* Source (place/time) of control group not 
described. 
* Analyses by gender, not mentioned in 
original hypotheses, undertaken 
* Cases were all inpatients - more severe? 
* Only (unvalidated) clinical interview 
used to assess childhood sexual abuse 
Willinger & 
Aschauer 
(2005) 
1 1 1  2 1 1   1 0 0   0 1  1  1 0 0   1  0 
12 
* Dysphonia cases were recruited 
consecutively - info not provided re 
controls 
* Cases recruited from specialist service; 
controls recruited from schools and 
acquaintances of students 
Anderson et 
al. (2007) 
1 1 0  2 0 1   1 0 0   0 1  1  1 1 1   0  0 
11 
* Reported that 80% of those eligible took 
part, but no actual Ns provided for majority 
of results (except PMD group for BSI). 
* No controlling for sig diffs in age, sex 
and educational achievement between 
groups. 
* BSI scores may have been confounded 
by QoL scores, and vice versa. 
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Study Downs and Black Checklist Item Total Notes 
 
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27* 
(max. 
18) 
 Seignourel et 
al. (2007) 
1 1 1  2 1 1   0 0 0   0 1  1  1 1 0   1  0 
12 
* Actual p-values not reported 
* No information regarding timing of 
recruitment 
Espirito-Santo 
& Pio-Abreu 
(2009) 
1 1 1  2 1 1   1 0 0   0 1  1  1 1 1   1  0 
14 
* Consecutive sampling used - however, 
not clear how participants were 
approached, if any declined etc. 
Stone, Warlow 
& Sharpe 
(2010) 
1 1 1  2 1 1   0 0 1   0 1  1  1 1 1   1  1 
15 
* Cases not recruited consecutively, and 
recruited from specialist services 
(limitation acknowledged by authors) 
* Commonest diagnosis in controls (MS) 
associated with depression 
* No power calculation relevant as study of 
incidence 
Voon et al. 
(2010) 
1 1 1  1 1 1   1 0 0   0 1  1  1 0 0   1  0 
11 
* No measure of IQ /education 
/employment status reported? 
Kranick et al. 
(2011) 
1 1 1  2 1 1   1 0 0   0 1  1  1 0 0   1  0 
12 
* Cases recruited from tertiary care - may 
be more severe than normal? 
* Not specified when controls were 
recruited? 
Parees et al. 
(2012) 
1 1 0  2 1 1   1 0 0   0 1  1  1 0 0   1  0 11 * No info re voluntary / consecutive 
recruitment of cases.  No info re timing.  
No info re inclusion/exclusion for controls. 
Voon et al. 
(2013) 
1 1 1  2 1 1   1 0 0   0 1  1  1 0 0   1  0 
12 
* Rater blinding not stated 
* Cases recruited from specialist clinic 
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Study Downs and Black Checklist Item Total Notes 
 
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27* 
(max. 
18) 
 DeMartini et 
al. (2014) 
1 1 0  1 1 1   1 0 0   0 1  1  1 0 0   1  0 
10 
* No info re source of healthy controls 
reported 
* No measure of IQ/education used 
Brown, 
Nicholson, 
Aybek, 
Kanaan, & 
David (2014) 
1 1 1  2 1 1   1 0 0   0 1  1  1 0 0   0  0 
11 
* Study was unable to recruit controls from 
same geographical area, so had to open up 
to opportunity sampling 
* Confounding effects of group diffs on IQ 
on anxiety/depression not investigated (as 
secondary measures) 
Aybek et al. 
(2014) 
1 1 0  2 1 1   1 0 0   1 1  1  1 0 0   1  0 
12 
* Reported that some participants excluded 
for "pragmatic reasons", but not reported 
what these were 
Steffen, Fiess, 
Schmidt & 
Rockstroh 
(2015) 
1 1 1  2 1 1   0 0 0   0 1  1  1 1 0   0  1 
12 
* Exact p-values not all provided 
* Info regarding recruitment (consecutive 
vs voluntary) not provided 
* Sig diff in years of education between 
cases and controls not controlled for 
van der 
Hoeven et al. 
(2015) 
1 1 1  2 1 1   1 0 0   0 1  1  1 1 0   1  0 
13 
* Recruitment of FMD and MD patients 
not consecutive 
* Healthy controls were spouses of MD 
patients - confounder? 
Aybek et al. 
(2015) 
1 1 1  2 1 1   1 0 0   0 1  1  0 1 0   1  0 
12 
* Participants recruited from specialist 
neuropsychiatry clinic, therefore more 
severe cases than average (?) 
* Unclear if raters were blind to 
case/control status 
* (Unvalidated) clinical interview used to 
assess sexual abuse history? 
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Study Downs and Black Checklist Item Total Notes 
 
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27* 
(max. 
18) 
 Fiess, 
Rockstroh, 
Schmidt, & 
Steffen (2015) 
1 1 1  2 1 1   1 0 0   0 1  1  1 0 0   1  0 
12 
* Timing of recruitment for cases and 
controls not reported 
Nicholson et 
al. (2016) 
1 0 1  2 1 1   1 0 1   0 0  1  0 0 0   0  1 
10 
* FMD cases drawn from specialist 
secondary and tertiary services -may not be 
representative 
* IQ scores not available for psychiatric 
controls 
* Healthy controls had sig. higher IQ than 
FMD group, not corrected for in analysis 
Fiess, 
Rockstroh, 
Schmidt, 
Wienbruch& 
Steffen (2016) 
1 1 1  2 1 1   1 0 0   0 1  1  1 0 0   1  0 
12 
* Timing of recruitment for cases and 
controls not reported 
Maurer et al. 
(2016a) 
1 1 1  1 1 1   1 0 0   0 1  1  1 0 0   1  0 
11 
* No measure of IQ /education 
/employment status reported? 
* Comment in discussion regarding FMD 
participants not necessarily being 
representative of all FMD patients 
* Unclear when controls were recruited? 
Maurer et al. 
(2016b) 
1 1 1  1 1 1   1 0 0   0 1  1  1 0 0   1  0 
11 
* No measure of IQ /education 
/employment status reported? 
* Unclear when controls were recruited? 
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Study Downs and Black Checklist Item Total Notes 
 
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27* 
(max. 
18) 
 Apazoglou, 
Mazzola, 
Wegrzyk, 
Polara & 
Aybek (2017) 
1 1 1  1 1 1   0 0 0   0 1  1  1 0 0   1  0 
10 
* "Current psychiatric condition such as 
[...] depression with acute suicidality" 
excluded; however "comorbidities such as 
anxiety or depression without suicidality" 
were included - effect on psychiatric 
outcomes? 
* No measure of IQ/education reported? 
Ekanayake et 
al. (2017) 
1 1 1  2 1 1   1 0 0   0 1  1  1 0 0   1  0 
12 
* PMD cases drawn from clinics, controls 
drawn from national database. 
* Not reported if PMD cases were 
consecutive or volunteered to participate 
Kienle et al. 
(2017) 
1 1 1  2 1 1   1 0 0   0 1  1  1 0 0   1  0 
12 
* Not reported where controls were drawn 
from 
* Not stated when recruitment took place 
Tomic et al. 
(2017) 
1 1 0  2 1 1   1 0 0   0 1  1  0 0 0   1  0 
10 
* Detailed inclusion/ exclusion criteria not 
provided 
* Query re the accuracy/validity of 
unstructured psychiatric interview? 
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Discussion 
The aim of this review was to explore psychosocial associates of motor and sensory 
functional symptoms, via a review of relevant case-control studies.  Several of the findings 
may offer support to the theoretical model proposed by Kanaan et al. (2017), which suggests 
that functional motor/sensory symptoms have a different etiology to functional seizures.   
Of the associates reviewed, the strongest evidence appeared to be for depressive 
symptoms, with all of the studies with healthy or organic disorder control samples finding 
evidence of elevated depressive symptomology in the functional symptoms samples.  By 
contrast, the findings on anxiety symptomology were mixed, with two-thirds of studies 
finding elevated rates of anxiety, and one-third finding no significant between-group 
differences.   
The association between depressive symptoms and FNS has been noted as far back as 
Janet’s (1907) original studies of functional symptoms, who referred to ‘general sentiments 
of dissatisfaction [and] incompleteness’, ‘innumerable lapses of the mental junctions, 
[including] incapacity of attention [and] memory’ and ‘seeming emotional [but] in reality 
feeling nothing vividly’, experiences that would correspond to symptoms of depression in 
modern classification systems.  Recent theoretical models of FNS (e.g. Brown, 2004) have 
not emphasized depressive symptoms as predisposing or precipitating factors for FNS, which 
may be because they are more strongly associated with some symptoms (e.g. motor/sensory 
symptoms) than others (e.g. seizures).  Although case-control studies can only establish that 
depressive symptoms are common correlates of functional motor/sensory symptoms, and not 
that they are causal, there was evidence in the reviewed studies that depressive symptoms 
may be a precipitant of functional motor/sensory symptoms, with both studies of people with 
recent onset symptoms (Binzer et al., 1997; Stone et al., 2010) finding the association with 
depressive symptoms to already be present at this early stage.  Including measures of FNS in 
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future prospective studies of people with depressive symptoms would be valuable in further 
exploring this hypothesis.   
Several explanations could be proposed for the more mixed findings on anxiety 
symptoms.  As previously mentioned, the small sample sizes of many of the reviewed studies 
may have meant that they were underpowered.  However, this limitation would also apply to 
the findings regarding depressive symptoms, making it less likely that this was the sole cause.  
An alternative explanation, as proposed in Brown and Reuber’s (2016) review of associates 
of functional seizures, is that people with functional symptoms either under-report, or lack 
awareness of, their anxiety.  This hypothesis is supported by a number of findings in the 
reviewed studies: Apazoglou et al. (2017) found a divergence between subjective and 
biological measures of stress in response to an experimental social stress test in their 
functional symptoms sample, but not in their control sample, indicating an altered awareness 
of stress reactivity in those with functional symptoms; and Stone et al. (2010) found that a 
significantly higher proportion of their functional symptoms sample had significant anxiety 
symptoms when assessed by a clinician-rated measure, but not when assessed by a self-report 
measure.  However, another study (Tomic et al., 2017) did not find this same pattern.  In 
addition, if the findings regarding anxiety were predominantly due to people with functional 
symptoms under-reporting or lacking awareness of their anxiety, one might also have 
expected them to under-report/lack awareness of other affective symptoms.  The findings 
regarding elevated depressive symptomology suggest that this was not the case.  
A third explanation for the mixed findings regarding anxiety, consistent with the 
theory of Kanaan et al. (2017), is that the association with functional motor/sensory 
symptoms may genuinely be less robust than the association between functional seizures and 
depressive symptoms.  Symptoms presenting as acute seizures may be more likely to be acute 
symptoms of anxiety that are not recognized as such (also referred to as ‘non-fearful panic’ 
PSYCHOSOCIAL ASSOCIATES OF MOTOR AND SENSORY FNS 46 
[Chen, Tsuchiya, Kawakami, & Furukawa, 2009]), a coping response to stress/anxiety that 
may have emerged as a developmental response to unescapable early-life trauma(s).  On the 
other hand, symptoms presenting as more chronic motor/sensory symptoms may represent an 
‘escape’ response to life stressors, arising from deficits in social problem-solving skills, 
which are also a common feature of depression (Nezu, 2004).  These differences may point 
towards an important area of differentiation between functional motor/sensory symptoms, 
and functional seizures.  
With regards to personality pathology, the initial findings from Binzer et al. (1997, 
1998) of high rates of personality disorder diagnoses in a sample of people with functional 
motor symptoms do not appear to have been supported by the (albeit limited) subsequent 
research.  This may be another area of difference between functional motor/sensory 
symptoms and functional seizures, as studies of functional seizure/PNES samples have found 
high rates of association (ranging from 10 to 86%) between functional seizures and 
personality disorders, especially borderline and other Cluster B disorders (Lacey, Cook, & 
Salzberg, 2007).  As there is strong evidence implicating childhood maltreatment and trauma 
in the subsequent development of personality disorders (e.g. Johnson, Cohen, Brown, 
Smailes, & Bernstein, 1999; Ball & Links, 2009), higher prevalence of personality disorders 
in people with functional seizures would also be supportive of Kanaan et al.’s (2017) theory 
that functional seizures are symptoms of a disorder of developmental origin, whereas 
functional motor/sensory symptoms are not.   
For functional motor/sensory symptoms, other features of personality may be more 
relevant than personality disorder diagnoses.  All of the reviewed studies that assessed 
alexithymic traits found that people with functional motor/sensory symptoms had 
significantly higher scores than those of healthy or organic neurological disorders control 
participants.  By contrast, studies of people with functional seizures have been much less 
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consistent in this area (Brown & Reuber, 2016).  Alexithymia has a significant impact on 
engagement with medical and psychological therapies (e.g. Lumley, Neely, & Burger, 2007), 
so further research into its role in FNS may be beneficial for refining theoretical models, as 
well as informing clinical practice.  
The findings of the reviewed studies with regards to childhood trauma were mixed, 
with stronger (though not unequivocal) evidence for emotional maltreatment, and weaker 
evidence for sexual or physical abuse.  By contrast, a meta-analysis by Sharpe and Faye 
(2006) estimated that the odds of having a history of childhood sexual abuse were almost 
three times greater for people with functional seizures, than for the general population.  A 
review of studies assessing prevalence of physical abuse in people with functional seizures 
(Fiszman, Alves-Leon, Nunes, D’Andrea, & Figueira, 2004) reported lifetime rates of 50-
77%, far greater than the prevalence rates reported in any of the studies in this review.   
There was, however, some consensus amongst the reviewed studies regarding 
significant life events/stressors precipitating the onset of functional symptoms, with six of the 
seven studies assessing recent events (i.e. in the year prior to symptom onset) finding 
significantly higher rates of relevant events (and/or subjective distress associated with them) 
in functional symptoms samples.  Tellingly, Nicholson et al. (2016) reported that a key event 
and/or a compelling psychological formulation could be generated for 91% of their 
participants with functional symptoms when a comprehensive, semi-structured assessment of 
life events was used, even though for 88% of this group, this key event had not been 
documented in their clinical notes.  On the basis of research findings that precipitating 
psychological stressors could not always be elicited in people with functional symptoms (e.g. 
Roelofs, Spinhoven, Sandijck, Moene, & Hoogduin, 2005), identifying psychosocial factors 
associated with symptom onset was downgraded from an essential diagnostic criteria to an 
‘associated feature supporting diagnosis’ in DSM-5 (APA, 2013) – this finding suggests that 
PSYCHOSOCIAL ASSOCIATES OF MOTOR AND SENSORY FNS 48 
such events may be more readily discoverable for those with functional motor/sensory 
symptoms, if appropriate methods are employed. 
This pattern of findings on childhood trauma and life stressors would be consistent 
with Kanaan et al.’s (2017) theory that functional motor/sensory symptoms are more likely to 
be an acute response to immediate stress, whereas functional seizures are the result of a 
developmental trauma.  Ekanayake et al.’s (2017) finding that the mean age at which people 
in a PNES sample experienced their most distressing traumatic event was significantly 
younger than those of people in functional movement disorder and healthy control samples 
(mean age 18.2 in PNES sample, vs 32.1 and 29.2 in FMD and HC samples, respectively), 
also points towards a different developmental trajectory for people with functional seizures, 
than for people with functional motor/sensory symptoms.    
 
Clinical and research implications 
The findings of this review highlight the diversity of psychosocial risk factors 
associated with functional motor/sensory symptoms, and the challenges of devising treatment 
approaches that apply to such a heterogeneous group.  Comorbidity of symptoms, both 
pseudoneurological and psychiatric, is widely acknowledged to be the norm, rather than the 
exception, in populations with functional symptoms (Şar, Akyüz, Kundakçi, Kiziltan, & 
Doğan, 2004).  Heterogeneity of symptoms and comorbidities underlines the importance of 
developing an individualized ‘neuro-bio-psycho-social’ formulation and treatment plan for 
those with FNS (McKee et al., 2018), which includes an assessment not only of the person’s 
symptoms and experiences, but also their subjective interpretation of them.  This review 
suggests that routine assessment of depressive symptoms, alexithymia, and recent life events 
may support clinicians to achieve this.    
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In advocating for a model of understanding distress that includes a broader 
consideration of the impact of psychosocial factors, rather than a model based on functional 
psychiatric diagnoses, Johnstone and Boyle (2018) point out that functional neurological 
disorders are one of the few diagnoses in the current psychiatric classification systems where 
the symptoms are explicitly acknowledged as responses to adverse psychosocial events or 
environments.  The findings of this review offer support for clinical approaches that consider 
the function of functional symptoms, and their relationship to significant events in a person’s 
life, rather than focusing on which neurological disorder they resemble. 
The findings of this review, regarding a possible association between functional 
motor/sensory symptoms, and childhood emotional abuse/neglect, low parental emotional 
warmth, and high parental rejection, may also suggest a novel direction for future research.  
Caregiver emotional under-involvement with children is thought to be a significant risk factor 
for subsequent impairments in reflective functioning (also known as mentalization) (Fonagy 
& Bateman, 2007).  Mentalization, defined as the ability to think about ourselves and others 
as having a mind (comprised of feelings, thoughts and intentions) (Subic-Wrana, 2011), is 
hypothesised to play a key role in the development of the ability to regulate one’s own 
emotions, as well as to distinguish the sensations of affective states from those of physical 
states.  Typically, these abilities are developed by a caregiver helping a child to make the 
implicit processing of emotions explicit, through the use of mirroring and the marking of 
affects, thus enabling them to differentiate their own inner states, and distinguish their own 
minds from those of others (Gergely & Watson, 1996).  However, impairments in the ability 
to mentalize have been found to emerge when a child’s affective expressions are consistently 
ignored by the caregiver, either due to emotional neglect, or because the caregiver themselves 
has difficulty distinguishing expressions of affective states (e.g. separation anxiety) from 
those of physical symptoms (Fonagy, Gergely, Jurist, & Target, 2002).  Difficulties with 
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recognising emotional states, and with distinguishing them from physical states and 
symptoms, have typically been ascribed to alexithymia in people with FNS.  For some 
people, however, these difficulties could plausibly be more usefully understood as a feature 
of an impairment in the ability to mentalize.  Mentalization, and the ways in which it overlaps 
with, or is separate from, alexithymia, has not previously been explored in people with FNS, 
and further research in this area may contribute towards an improved understanding of the 
etiology of FNS.      
 
Conclusion 
 
The findings of this review of studies from nine different countries, spanning over 20 
years of research, highlight the diversity of psychosocial associates of functional motor and 
sensory symptoms.  While many of these are undoubtedly also common to functional 
seizures, there appear to be areas of subtle difference, particularly regarding depressive 
symptoms, personality pathology, precipitating life events, and childhood adversity.  These 
findings offer tentative support to a perspective that functional neurological symptoms may 
be more helpfully conceptualised by their manner of presentation (acute vs chronic) and their 
relationship to stress and trauma (recent vs developmental), than by their equivalence to 
neurological conditions.  Greater focus on the function of the functional neurological 
symptom(s) may enable better understanding of the symptom, and of its role for the person 
experiencing it, and lead to the development of treatment approaches that are more flexible, 
engaging, and helpful. 
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Abstract 
Objective: Alexithymia and hypomentalization, two traits associated with childhood 
emotional abuse/neglect, have not previously been studied in people with mixed-symptom 
functional neurological disorder (FND).  This study examined whether these traits were more 
prominent in people with FND than in healthy control participants, and explored the 
relationships between alexithymia, hypomentalization, and somatic/neurological symptoms 
of a generalized nature. Method: Twenty-nine participants with FND and 41 healthy control 
participants completed a battery of self-report measures.  Between-group differences in 
alexithymia and hypomentalization were investigated using parametric tests, and binary 
logistic regression analyses examined whether alexithymia and hypomentalization were 
predictive of FND (vs control) group status, after controlling for depressive symptoms, 
anxiety symptoms and education attainment.  Linear regression analyses examined whether 
alexithymia and hypomentalization were associated with physical and neurological symptoms 
across the entire sample of FND group and control group participants. Results: Participants 
with FND had significantly higher scores on measures of alexithymia, hypomentalization, 
somatic symptoms and neurological symptoms, than healthy control participants.  Between-
group differences in alexithymia and neurological symptoms remained significant after 
controlling for covariates.  High scores on the alexithymia and mentalization measures were 
also predictive of high scores on the measures of somatic and neurological symptoms across 
the entire sample. Conclusion: Alexithymia and hypomentalization appear to be significant 
issues for people with FND, and may contribute to the tendency to express distress via 
physical symptoms.  Exploring these traits with individual service users may contribute to a 
more comprehensive conceptualisation of their difficulties, and inform the development of 
future treatment approaches. 
Key words: functional neurological disorder (FND), mentalization, alexithymia,  
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Alexithymia, mentalization and symptom complexity in functional neurological disorder (FND) 
Introduction 
Definition and theoretical model 
Functional neurological disorder (FND) is a condition characterised by symptoms of 
altered motor or sensory function, which are incompatible with recognized neurological or 
medical conditions, and which cause clinically significant distress and/or impairment in 
functioning (American Psychiatric Association, 2013).  Common symptoms of FND include 
abnormal motor movements, weakness or paralysis; disturbances of speech or swallowing; 
sensory loss or anaesthesia; and dissociative attacks or seizures (also commonly known as 
psychogenic non-epileptic seizures or PNES).  
As the symptoms of FND commonly resemble those of neurological disorders (such 
as Parkinson’s disease, stroke or epilepsy), individuals with FND are often first seen in 
neurology clinics - Stone et al. (2009) reported that 30% of 3,781 service users seen at 
Scottish neurology clinics between December 2002 and February 2004 had neurological 
symptoms that were “Not at all” or only “Somewhat” explained by organic disease.  If all 
symptoms (not just the presenting one) are considered, up to 61% of neurology service users 
have been reported to have functional symptoms (Fink, Hansen & Søndergaard, 2005).  
Estimates of the prevalence of FND range from 4-50 per 100,000 population per year, 
depending on the definition used (Carson et al., 2012).  Due to the heterogeneity of 
symptoms, and their apparent overlap between the neurological and the psychological, FND 
was traditionally an “orphan disorder”, with no single discipline keen to assert ownership of 
it (Baslet, Dworetzky, Perez, & Oser, 2015).  There is now a growing consensus that an inter-
disciplinary, ‘neuro-bio-psycho-social’ approach to the assessment, formulation and 
treatment of FND is essential (Carson et al., 2012; Brown & Reuber, 2016; McKee et al., 
2018). 
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In recent years, Richard Brown’s (2004) integrative conceptual model has become a 
highly influential theoretical model of FND (Carson et al., 2012; Reuber & Brown, 2017).  
The model explicitly synthesises useful concepts from previous dissociation, conversion, and 
somatization models of FND, as well as integrating ideas and research from cognitive, social 
constructionist and neurobiological approaches.   
Drawing on dissociation models (e.g. Janet, 1889, 1907; Oakley, 1999), the 
integrative conceptual model theorises that FND is the product of disturbances of the 
cognitive attentional system.  It hypothesises that human actions are controlled via two 
mechanisms.  Routine behaviours are controlled by a primary attentional system (PAS), 
which chooses the required attentional, cognitive and motor processes from previously 
learned mental models (schemata).  This process requires little conscious effort, and is 
experienced as intuitive and automatic.  For novel or complex behaviours, however, where 
there is no existing schemata, a secondary attentional system (SAS) is required, which draws 
on information from existing schemata that appears relevant, and from sensory input(s).  
Processing controlled by the SAS feels more effortful and demanding of conscious control – 
it is these processes that we are more aware of controlling.  The integrative conceptual model 
suggests that functional symptoms arise when the PAS and SAS are activated 
inappropriately. It suggests that some symptoms (e.g. functional motor tremors), where a 
behaviour should be under the control of the SAS, become controlled by the PAS, leading to 
dissociation between the action and the experience of subjective volition; other symptoms 
(e.g. functional motor paralyses) develop when existing schemata (controlled by the PAS) are 
more compelling than the information being provided by the environment or the senses, 
leading to symptoms that are inconsistent with the objective sensory world, but are 
experienced by the person as subjectively ‘real’ (Brown, 2002). 
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Brown’s model suggests that these compelling schemata (‘rogue representations’) 
may have their origins in exposure to certain physical states in the self (e.g. distressing and 
memorable physical symptoms of anxiety) or in others (e.g. illness or disability in 
family/friends).  They may also develop via sociocultural transmission of illness 
representations: Reuber and Elger (2003), for example, report that a high proportion of 
functional seizures involve asynchronous limb movements, side-to-side head shaking, and 
closed eyelids, symptoms which are relatively rare in epileptic seizures, but are what people 
‘expect’ to happen in a seizure. 
Drawing on somatization theories, Brown’s model suggests that the likelihood of 
developing FND is increased by factors such as heightened body-focussed attention, 
misattribution of the cause of symptoms, illness worry and rumination, and illness behaviour 
(the so-called “secondary gains” of FND, such as increased care or attention from others, or 
avoidance of unwanted tasks/responsibilities).   
Finally, echoing conversion theories (e.g. Breuer & Freud, 1893-1895/1982), the 
model also integrates findings that childhood trauma is common in people with FND (e.g. 
Fiszman, Alves-Leon, Nunes, D’Andrea, & Figueira, 2004; Section A of this thesis). 
Increased body focus is hypothesised as acting as a defence against the overwhelming 
negative affect or cognition associated with trauma, which can be adaptive in the short term, 
but become maladaptive in the long term.  This element of the model has been further 
expanded recently, with the suggestion that acute functional symptoms (e.g. functional 
seizures, paroxysmal movement disorders) may be the result of a developmental disorder 
with its origins in childhood trauma, while chronic symptoms are an idiosyncratic coping 
response to acute life stressors (Kanaan et al., 2017). 
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Treatments and prognosis 
Although Brown’s model has advanced understanding of the psychological 
mechanisms underpinning FND, there remains limited consensus as to how to translate this 
understanding in to therapeutic practice (LaFrance, Rusch, & Machan, 2008).  A Cochrane 
review of psychosocial interventions for FND (Ruddy & House, 2005) found only three 
relevant treatment studies, and these were assessed as offering only slight evidence in favour 
of help rather than harm, in terms of engagement, mental state, and physical functioning.  
Since this review, randomised controlled treatment trials of cognitive behaviour therapy-
informed psychotherapy (Goldstein et al., 2010; LaFrance et al., 2014), cognitive behaviour 
therapy with guided self-help (Sharpe et al., 2011), and integrated inpatient physiotherapy 
and psychotherapy (Jordbru, Smedstad, Klungsøyr, & Martinsen, 2014; Nielsen et al., 2015) 
have been published.  These, and other published case-series and uncontrolled treatment 
studies, have generally had small sample sizes and methodological limitations, and so are still 
considered recommendations for further research at this time (Perez & LaFrance, 2016). 
An additional obstacle to treatment is that people with FND are often reluctant to 
engage with psychological interventions.  Several studies have reported that more than half of 
service users with FND referred for psychological therapies do not engage with them 
(Howlett, Grunewald, Khan, & Reuber, 2007; Baslet & Prensky, 2013). One potential reason 
for this is that many people with FND continue to attribute their symptoms to an 
undiscovered physical cause after the diagnosis of FND is confirmed, even though 
misdiagnosis of functional symptoms is actually very rare (Stone et al., 2005; Stone et al., 
2009).  Paradoxically, people with FND are also often less likely than those with organic 
disorders to attribute their symptoms to psychological factors, including stress (Stone, Binzer 
and Sharpe, 2004; Stone, Warlow, & Sharpe, 2010; Ludwig, Whitehead, Sharpe, Reuber, & 
Stone, 2015). 
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Currently, the prognosis for people with FND remains poor (Carson et al., 2012). 
Gelauff, Stone, Edwards, and Carson (2014) reported that more than one-third of people with 
FND had the same or worse symptoms when re-assessed (on average) 7.4 years later, while 
Durrant, Rickards, and Cavanna (2011) found that 40% or less of those diagnosed with 
functional seizures as adults achieved seizure remission five years after diagnosis, compared 
to 60-80% of those with epileptic seizures.  Individuals with FND have been found to have 
levels of distress, disability and healthcare usage equal to, or even greater than, those of 
individuals with equivalent organic neurological disorders (Anderson et al., 2007; Carson et 
al., 2011).  Research has also found that over 70% of people with functional seizures were 
treated with inappropriate and potentially harmful anticonvulsant medications prior to 
diagnosis (Reuber, Fernández, Bauer, Helmstaedter, & Elger, 2002; de Timary et al., 2002), 
highlighting that FND can have a significant impact on physical, as well as psychological, 
well-being. 
 
Revisiting childhood emotional adversity   
The combination of unexplained symptoms, reluctance to engage with psychological 
models, and poor prognostic outcomes, suggests that the dominant conceptualisations of FND 
remain incomplete.  One consistent research finding, that may have important implications 
for the understanding and treatment of FND, is that people with FND have high rates of 
childhood emotional/psychological adversity.  Brown and Reuber’s (2016) review of 
psychological associates of functional seizures found that people with functional seizures 
reported higher rates of childhood emotional abuse/neglect than control participants in each 
of the six case-control studies that had explored this area.  One of these studies (Salmon, Al-
Marzooqi, Baker, & Reilly, 2003) also found childhood emotional abuse was a unique 
predictor of functional seizure (versus epilepsy) status, but physical or sexual abuse were not 
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(although it was no longer a significant predictor after controlling for other family 
characteristics).  A review of published case-control studies of functional motor and sensory 
symptoms (Section A of this thesis) also found that these studies frequently reported higher 
rates of childhood emotional abuse/neglect in FND samples, while the findings regarding 
childhood sexual and physical abuse were more variable. 
A number of consequences of childhood emotional abuse/neglect may be of relevance 
to the subsequent development of functional symptoms, the rejection of psychological causes 
for the symptoms, and the limited efficacy of psychological treatments.  One outcome of 
childhood emotional abuse/neglect that has been suggested is alexithymia in later life 
(Zlotnick, Mattia, & Zimmerman, 2001; Aust, Härtwig, Heuser, & Bajbouj, 2013).  
Alexithymia describes a cluster of cognitive and affective features, characterised by difficulty 
identifying and describing feelings, difficulty distinguishing between emotions and bodily 
sensations of emotional arousal, restricted imagination and fantasy, and externally-oriented 
thinking (Taylor, 2000).  It is generally considered to be a personality trait, with a high 
degree of stability over time (Aust et al., 2013), and it is of particular relevance to FND, as it 
was first described in the 1970s among people with classic psychosomatic symptoms 
(Sifneos, 1973).   
Two mechanisms for the influence of alexithymia on FND have been suggested by 
Brown and Reuber (2016).  Motivation not to recognise emotional states (because strong 
affect is seen as unacceptable or unmanageable), coupled with a tendency to suppress 
emotions, may lead to a heightened focus on the physical aspects of emotions.  Alternatively, 
alexithymia may reflect intrinsic deficits in recognising, describing and thinking about 
emotions, potentially with neurodevelopmental origins.  Functional symptoms may therefore 
be symptoms of affective arousal incorrectly interpreted as symptoms of a physical disorder, 
or they may act as a release mechanism for unrecognised emotional tensions.   Alexithymia 
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has previously been studied in populations of people with functional seizures (e.g. Kaplan et 
al., 2013) and functional motor symptoms (e.g. Demartini et al., 2014); however, these 
studies typically excluded people with mixed functional symptoms, so it has not yet been 
established whether these findings would generalize to the heterogeneous FND population 
typically seen by NHS neuropsychiatry services. 
A potential alternative, or additional, outcome of childhood emotional abuse/neglect 
is impairment of reflective functioning, or mentalization.  Mentalization is the ability to think 
about ourselves and others as having a mind (comprised of feelings, thoughts and intentions), 
which enables us to be aware of our emotions, and to regulate them by thinking about them 
(Subic-Wrana, 2011).  The ability to mentalize is thought to develop in early childhood, when 
a caregiver helps a child to make the implicit processing of emotions explicit, through the use 
of mirroring and the marking of affects.  This enables a child to learn to distinguish between 
his/her own inner states, and those of others (Gergely & Watson, 1996).  However, if the 
affective expressions of a child are consistently undetected by the caregiver, either due to 
emotional neglect, or because the caregiver themselves cannot distinguish the expressions of 
affective states (e.g. separation anxiety) from those of physical symptoms, then impairments 
may develop in the ability to distinguish between one’s own mental states and those of 
others, and in the ability to develop mental representations of the physical sensations that 
belong to particular affective states (Fonagy, Gergely, Jurist, & Target, 2002).  While deficits 
in mentalization are currently most commonly associated with the symptoms of borderline 
(emotionally unstable) personality disorder diagnoses (Fonagy & Luyten, 2009), this last 
element of mentalization theory, regarding the influence of mentalization on the ability to 
differentiate between emotional distress and physical distress, may also be highly relevant to 
the understanding FND.   
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Assessment of mentalization has previously only been possible by using the 
Reflective Functioning Scale (Fonagy, Target, Steele, & Steele, 1998) to rate the Adult 
Attachment Interview (George, Kaplan & Main, 1996), which has limited research value due 
to issues with the practicality, cost and duration of the measure (Badoud et al., 2015).  
However, a self-report measure, the Reflective Functioning Questionnaire (RFQ; Fonagy et 
al., 2016), has recently been developed as a brief screening measure of reflective functioning.  
The measure looks at two elements of mentalizing (certainty about mental states, and 
uncertainty about mental states), enabling evaluation of the tendency to hypermentalize (i.e. 
to develop models of the mind that go far beyond the available evidence) and to 
hypomentalize (i.e. to be unwilling or unable to develop models of the mind that are 
realistically nuanced and opaque) (Badoud et al., 2015).  This study is the first to assess 
reflective functioning, and to do so using the RFQ, in a typical UK FND population. 
 
Aims and hypotheses 
Based on theory, and on the research findings described above, the aim of this study 
was to explore whether alexithymia, and/or difficulties with mentalizing, are more common 
in people with FND, than in people without FND.  Exploring these areas is important as this 
may lead to the refinement theoretical models of FND, and may also have implications for 
treatment approaches for FND, particularly those reliant on emotional awareness and insight, 
as many psychological therapies are.   
Alexithymia has previously been found to be associated with lower educational 
attainment (Lane, Sechrest, Riedel, 1998; Salminen, Saarijärvi, Äärelä, Toikka, & Kauhanen, 
1999), and with symptoms of depression (Honkalampi, Hintikka, Tanskanen, Lehtonen, & 
Viinamäki, 2000) and anxiety (Berthoz, Consoli, Perez-Diaz, & Jouvent, 1999).  As a result, 
measures of these variables were included in the study, so they could be examined as 
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covariates.  To expand the exploration beyond categorical diagnoses of FND, measures of 
common somatic and neurological symptoms were also included, in order to examine 
whether alexithymia and mentalization would be predictive of people experiencing more 
physical symptoms, regardless of whether or not they had FND.   
The study therefore aimed to test the following hypotheses: 
i. Individuals with FND will, on average, have greater impairments in their ability to 
understand and describe emotions (i.e. alexithymia), than healthy control participants. 
ii. Individuals with FND will have a greater tendency to hypomentalize (an impairment 
of reflective functioning characterized by low certainty, and high uncertainty, about 
mental states in one’s self and others), than healthy control participants.  
iii. Individuals with FND will describe, on average, more somatic and neurological 
symptoms of a generalized nature, than healthy control participants (as they ascribe 
symptoms of affective arousal to physical defects). 
iv. Higher levels of alexithymia and hypomentalizing will predict FND (versus control) 
group membership in a logistic regression, when educational attainment, depressive 
symptoms, and anxiety symptoms are controlled for.  
v. Higher levels of alexithymia and hypomentalizing will predict higher levels of 
somatic/neurological problems of a generalized nature, in linear regression analyses 
of the FND and control groups combined. 
 
Methods 
Design 
A cross-sectional, between-groups design was employed, with two groups of 
participants – one group of service users with a diagnosis of FND (the FND group), and one 
group of individuals with no history of FND (the healthy control group). 
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Participants 
A target sample size of 26 participants per group was chosen, based on Cohen’s (1992, p. 
158) calculation to detect large effect sizes in independent two-sample t-tests, with 
conventional levels of significance (.05) and statistical power (80%).  For the logistic 
regression analyses, this sample size also allowed for up to eight predictors to be included in 
the models, with sufficient power to detect a large effect size.  For the linear regression 
analyses, a sample size of 52 allowed for a medium-large effect size to be detected.  
Recruitment of service users with a diagnosis of FND took place at two tertiary 
neuropsychiatry services in England between October 2017 and March 2018.  Recruitment 
continued until the target of 26 participants was reached. Eligibility for the study was 
confirmed by an experienced neuropsychologist or neuropsychiatrist, on the basis of a review 
of electronic medical records. 
Recruitment of the healthy control group took place between January and March 
2018, via an email invitation sent to university staff and students, and an advertisement on 
social media.  Additional participants were recruited for the healthy control group, in the 
hope that the groups could be matched on educational attainment, but as this did not prove 
possible, instead all participants were included in the control group and educational 
attainment was controlled for as a covariate. (The implications of this are discussed further in 
the Limitations section.) 
Inclusion criteria for both groups were being aged 18 or over, and being able to read 
English or access support to do so (in order to complete the questionnaires).  Having a 
diagnosis of FND was an inclusion criterion for the FND group.  Individuals with a primary 
diagnosis of chronic pain were excluded from the FND group, as this condition commonly 
has an organic etiology, such as arthritis/osteoarthritis, traumatic injury or surgery (Breivik, 
Collett, Ventafridda, Cohen, & Gallacher, 2006).  Individuals with a primary diagnosis of 
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ME/chronic fatigue syndrome were also excluded, as these conditions are thought to often be 
associated with abnormalities of the central nervous system, immune system or 
neuroendocrine regulation system (Afari & Buchwald, 2003).  Control group participants 
were excluded if they self-reported a current diagnosis of a neurological, psychiatric or 
serious physical health condition.  Full demographic details of the two groups of participants 
are presented in the Results section.    
Written or electronic informed consent was gained from all participants.  The study 
was approved by the UK National Research Ethics Service, the Health Research Authority, 
and the relevant NHS Research and Development departments (Appendices 2-6).  
 
Materials 
A battery of self-report questionnaire measures was used to assess the variables of 
interest.  For reference, all of the measures are presented in full in Appendix 7. 
Alexithymia was measured via the Toronto Alexithymia Scale (TAS-20; Bagby, 
Taylor, & Parker, 1994a, 1994b), a 20-item questionnaire which generates scores for 
alexithymia sub-domains of Difficulty Identifying Feelings (TAS_DIF), Difficulty 
Describing Feelings (TAS_DDF), and Externally-Oriented Thinking (TAS_EOT), as well as 
an overall score for alexithymia (TAS_20_TOTAL).  Participants were asked to rate their 
agreement with statements such as “I am often confused about what emotion I am feelings” 
on a five-point Likert-type response scale ranging from “strongly disagree” to “strongly 
agree”.  Higher agreement generated higher scores on 15 of the measure items, and five items 
(e.g. “Being in touch with emotions is essential”) were reverse scored.  Overall scores for 
alexithymia range from 20-100, with scores of ≥ 61 indicative of alexithymia (Taylor, Bagby, 
& Parker, 1997).  The total and subdomain scores have been shown to have acceptable 
internal reliability (TAS_20_TOTAL, α = 0.86; TAS_DIF, α = 0.80; TAS_DDF, α = 0.76; 
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TAS_EOT, α = 0.71) (Parker, Taylor, & Bagby, 2003).  The internal reliabilities of the 
TAS_20_TOTAL (α = 0.92), TAS_DIF (α = 0.93) and TAS_DDF (α = 0.84) scales in this 
study were broadly equivalent to that reported in previous studies; however, as reported in 
other studies (e.g. Kooiman, Spinhoven, & Trijsburg, 2002) the internal consistency of the 
TAS_EOT scale was notably lower (α = 0.66), and the results regarding this measure should 
be interpreted with this in mind.   
Mentalizing was measured via the Reflective Functioning Questionnaire (RFQ; 
Fonagy et al., 2016).  The RFQ is comprised of two subscales: the Certainty about Mental 
States subscale (RFQ_C) and the Uncertainty about Mental States subscale (RFQ_U).  Both 
subscales consist of six items, which participants were asked to rate on a seven-point Likert 
scale ranging from “completely disagree” to “completely agree”. For the RFQ_C subscale, 
low levels of agreement with statements such as “People’s thoughts are a mystery to me” 
lead to high scores (indicating hypermentalizing), and lower scores signify normal levels of 
certainty about mental states.  For the RFQ_U subscale, high levels of agreement with 
statements such as “I don’t always know why I do what I do” lead to high scores (indicating 
hypomentalizing), and lower scores signify normal levels of uncertainty about mental states. 
The total score on each subscale is calculated as the mean of the six responses, and ranges 
from 0-3.  Initial analyses (Badoud et al., 2015) of the six-item scales reported acceptable 
internal consistency for the subscales (RFQ_C: α = 0.72; RFQ_U: α = 0.64).  The internal 
consistency of the subscales in this sample was also acceptable (RFQ_C: α = 0.73; RFQ_U: α 
= 0.78).   
Depressive symptoms were assessed using the Patient Health Questionnaire 
depression scale (PHQ-8; Kroenke & Spitzer, 2002), an 8-item measure used widely in 
research (e.g. Strine et al., 2008) and clinical practice (Kroenke et al., 2009).  The PHQ-8 
assesses the frequency with which common symptoms of depression (e.g. “Feeling down, 
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depressed or hopeless”) have been experienced in the previous two weeks, on a four-point 
response scale (“Not at all” = 0; ” Some days” =1; “More than half the days” = 2; “Nearly 
every day” = 3).  Total scores range from 0-24, with a cut-off score of ≥ 11 suggested as 
having the best trade-off between sensitivity and specificity for indicating a major depressive 
disorder diagnosis (Manea, Gilbody, & McMillan, 2012).  The measure has previously been 
reported to have good internal consistency (α = 0.86 - 0.89) (Smarr & Keefer, 2011), and 
internal consistency in this study was also good (α =  0.94). 
Anxiety symptoms were assessed using the Generalized Anxiety Disorder scale 
(GAD-7; Spitzer, Kroenke, Williams, & Löwe, 2006).  This seven-item scale assesses 
common symptoms of anxiety (such as “Feeling nervous, anxious or on edge”) in the 
previous two weeks, using the same four-point Likert-type response scale as the PHQ-8.  
Scores range from 0-21, with a cut-off score of ≥ 10 suggested as having the best sensitivity 
and specificity for clinically significant anxiety (Löwe et al., 2008).  The measure has been 
reported to have acceptable internal consistency (α = 0.89) (Löwe et al., 2008), which was 
also found in this study (α = 0.93). 
Comorbid physical health symptoms of a generalized nature were assessed via a 
checklist of 14 symptoms, based on the Patient Health Questionnaire Somatic Symptom 
Severity Scale (PHQ-15; Kroenke, Spitzer, & Williams, 2002) (referred to hereafter as the 
PHQ-15 checklist).  The measure assesses the presence of fourteen common somatic 
symptoms (such as back pain, headaches and digestive difficulties) over the previous four 
weeks. One item (regarding pain related to menstruation) is gender specific, and was 
excluded to make the data consistent across the sample, as per Witthöft, Hiller, Loch and 
Jasper (2013).  On the PHQ-15, participants are asked to rate whether they have been “Not 
bothered at all” (scoring 0), “Bothered a little” (1), or “Bothered a lot” (2) by the symptoms 
over the previous four weeks.  This scale is reported as having acceptable internal 
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consistency (α = 0.80) and test-retest reliability (intraclass correlation = 0.65) (Han et al., 
2009).  Due to a coding error, only six participants completed the measure using a three-point 
response scale, with the remaining participants instead rating whether the symptoms were 
absent (scoring 0) or present (1) over the previous four weeks.  To explore the reliability of 
this scoring system, the data from the six participants who completed the full measure was 
recoded to the same present/absent scale (“Not bothered at all” = 0; “Bothered a little” or 
“Bothered a lot” = 1).  The scores of the two rating scales correlated significantly (R = 0.81, p 
= 0.049), and the internal consistency of the measure with a present/absent rating scale was 
also adequate (α = 0.85), so a decision was made to retain this measure.  Potential scores on 
this measure therefore ranged from 0-14. 
Finally, neurological symptoms were measured via a common neurological symptoms 
checklist, developed by Carson et al. (2014) (referred to hereafter as the Neuro checklist).  
Participants were asked to indicate whether or not they had experienced 10 common 
neurological symptoms (such as paralysis or weakness, loss of sensation, or seizures/fits) in 
the past month. Each endorsed item was allocated a score of one point, leading to a range of 
total scores from 0-10.  The internal consistency of this measure in the current study was 
acceptable (α = 0.86). 
 
Procedure 
Service users with FND, who were identified as being eligible for the study, were 
approached about participation in the study via a letter or a verbal invitation from a clinician 
at their service.  After reading the Participant Information Sheet (Appendix 8), interested 
FND group participants were asked to either complete the consent form (Appendix 9) and 
questionnaires measures on paper forms, and to return these in the post, or alternatively, to 
visit an online survey website (www.qualtrics.com) and complete the consent form and study 
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measures electronically.  Control group participants were invited (via email and 
advertisements on social media) to visit the same online survey website, where a Participant 
Information Sheet (Appendix 10) was available.  Interested participants could then complete 
an online consent form (Appendix 11) and the study measures on the survey website.  
In order to safeguard participants from harm, the Participant Information Sheets 
advised all participants of sources of emotional support that they could access if they found 
taking part in the study distressing.  Participants with FND were also advised that they could 
contact the collaborating clinicians at their neuropsychiatry service if they wished to discuss 
any aspects of the study further. 
In total, of the 65 service users with FND asked to participate, 29 (44.6%) agreed to 
take part, along with 42 healthy control participants.  All 71 participants who started the 
measures completed them in full. 
 
Analysis 
Data from the study measures were analysed using SPSS (version 24).  Means and 
SDs were calculated for continuous variables, and frequencies and percentages for 
categorical variables.  Across all participants and measures, less than 0.1% of questionnaire 
responses were missing, with no more than one item missing on any one measure.  Where no 
formal rules were available for managing missing data, missing items were replaced by the 
mean of the remaining items on the scale.   
To explore between-group differences on measures of interest (Hypotheses i-iii), a 
series of t-tests were undertaken.  Exploratory analyses of the data were conducted first, to 
establish whether the necessary assumptions for parametric tests were met.  Kolmogorov-
Smirnov tests for each group of participants revealed that data from a number of the measures 
(TAS_DIF, RFQ_C, RFQ_U, PHQ-15 checklist, PHQ-8, GAD-7, and Neuro Checklist) did 
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not meet the assumption of normal distribution.  Levene’s tests for homogeneity of variance 
were significant (p < .05) for the RFQ_U, PHQ-15 checklist, PHQ-8, GAD-7 and Neuro 
checklist, indicating that the assumption of equal variance was not met for these variables.  
As recommended by Wright, London, and Field (2011), bootstrap estimation was used on all 
of the parametric analyses as a more conservative measure.  Significance values and 
confidence intervals are reported from the bootstrap analyses, as well as the test statistics and 
significance values from the parametric tests. 
For Hypothesis iv, a series of hierarchical logistic regression analyses were 
undertaken, with group status (FND or control group) entered as the dependent variable; the 
PHQ8, GAD7 and educational attainment measures entered in the first block (as confounding 
variables); and the predictor of interest entered in the second block. Eight separate 
regressions were conducted, one for each of the eight predictors of interest 
(TAS_20_TOTAL, TAS_DIF, TAS_DDF, TAS_EOT, RFQ_C, RFQ_U, PHQ-15 checklist, 
and Neuro checklist).  Prior to these analyses, the assumptions for logistic regression analyses 
were tested, as per Field (2013).  The assumption of linearity of the logit was met, as the 
interactions between each of the predictors and the log of itself were not significant (all p > 
.05).  Examination of the collinearity between variables indicated that all of the variables’ 
Variance Inflation Factor indices were below 10, and the tolerance values were above 0.1, 
indicating that the assumption of no collinearity was met, with the exception of the PHQ-8.  
Bivariate correlations indicated that this measure correlated highly with one of the other 
covariates (the GAD-7), but also with one of the predictors of interest (the PHQ-15).  As a 
result, the results of this particular regression should be interpreted with caution.  
For Hypothesis v, six separate linear regressions were undertaken, with 
TAS_20_TOTAL, RFQ_C, and RFQ_U entered in to models as predictor variables, and the 
PHQ-15 checklist and Neuro checklist scores entered as dependent variables for each 
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predictor.  Prior to the analyses, the scatterplots of standardised predicted values versus 
standardised residuals were examined, to establish if the data met the assumptions of 
homogeneity of variance and linearity, and if the residuals were approximately normally 
distributed.  Some mild variations were noted, therefore bootstrap estimation of the linear 
regression analyses was used as a more conservative method (Wright et al., 2011). 
Results 
Demographic and clinical characteristics 
The demographic and clinical characteristics of the total sample, and of the FND and 
control groups, are presented in Table 1.  There were no significant between-group 
differences in gender (Fisher’s exact test, p = 1.00) or mean age (t[42.71] = -.948, p = .349).  
There was a significant between-group difference on ethnicity, with a higher proportion of 
participants of White ethnic background in the control group (Fisher’s exact test, p = .018).  
In order to compare the educational attainment of the groups, attainment was ranked on a 
scale from one to eight, in accordance with UK Regulated Qualification Framework (Office 
of Qualification and Examination Regulations, 2015).  There was a significant between-group 
difference (FND group Mdn = 3.50, Control group Mdn = 7.00; U = 136.00, z = -5.09, p < 
.001), with educational attainment, on average, higher in the control group. 
On the measure of depressive symptoms (PHQ-8), FND group participants, on 
average, scored higher than control group participants and the difference, -10.51, BCa 95% 
CI [-13.08, -7.69], was significant, t(47.10) = -7.38, p < .001, representing an effect size of d 
= 2.23.  A significantly higher proportion of the FND group also scored above the clinical 
cut-off of 11 on the depression measure (69% vs 11.9%, Fisher’s exact test, p < .001).   
FND group participants, on average, scored higher than control group participants on 
the measure of anxiety (GAD-7), and the difference, -7.02, BCa 95% CI [-9.59, -4.34], was 
significant, t(46.26) = -5.19, p < .001, representing an effect size of d = 1.60.   A significantly  
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Table 1.  
Demographic and clinical characteristics of study participants 
 Total sample  
(N=71) 
n (%) 
FND group 
(n=29) 
n (%) 
Control group 
(n=42) 
n (%) 
Gender        
     - Female 58 (81.7) 24 (82.8) 34 (81.0) 
     - Male 13 (18.3) 5 (17.2) 8 (19.0) 
Ethnicity    
     - White 64 (90.1) 22 (75.9) 42 (100) 
     - Other 4 (5.6) 4 (13.8) 0 
     - Not stated/Prefer not to say 3 (4.2) 3 (10.3) 0 
Educational attainment    
     - GCSE Grades D-G (1) 1 (1.4) 1 (3.4) 0 
     - GCSE Grades A*-C (2) 9 (12.7) 8 (27.6) 1 (2.4) 
     - A Level (3) 4 (5.6) 3 (10.3) 1 (2.4) 
     - Certificate of Higher Education (4) 2 (2.8) 1 (3.4) 1 (2.4) 
     - Diploma of Higher Education (5) 5 (7.0) 3 (10.3) 2 (4.8) 
     - Bachelor’s Degree (6) 16 (22.5) 6 (20.7) 10 (23.8) 
     - Master’s Degree / Postgraduate 
Certificate/Diploma (7) 
25 (35.2) 2 (6.9) 23 (54.8) 
     - Doctorate (8) 4 (5.6) 0 4 (9.5) 
     - Not stated/Prefer not to say 5 (7.0) 5 (17.2) 0 
    
 Mean (SD) Mean (SD) Mean (SD) 
Age 36.23 (12.77) 38.10 (16.04) 34.93 (9.92) 
Clinical comorbidity    
     - PHQ8   14.91 (6.60) 4.40 (4.70) 
     - GAD7   12.31 (6.31) 5.29 (4.39) 
    
  n (%) n (%) 
Scoring above clinical cut-off for 
depression (≥ 11 on PHQ8) 
 20 (69.0) 5 (11.9) 
Scoring above clinical cut-off for 
anxiety (≥ 10 on GAD7) 
 20 (69.0) 7 (16.7) 
 
higher proportion of the FND group also scored above the clinical cut-off of 10 on the 
anxiety measure (69% vs 16.7%, Fisher’s exact test, p < .001). 
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Hypothesis i 
The mean scores of the TAS-20, the TAS-20 subscales, RFQ_C, RFQ_U, PHQ-15 
checklist, and Neuro checklist are presented in Table 2.   
The first hypothesis was that participants with FND would have significantly greater 
alexithymic traits than control participants.  Consistent with the hypothesis, on average, FND 
group participants had higher scores on the TAS-20, and the difference, -21.90, BCa 95% CI 
[-28.55, -15.78], was significant t(69) = -7.43, p < .001, representing an effect size of d = 
2.06.  A significantly higher proportion of the FND group also scored above the clinical cut-
off (≥61) on the measure (55.2% vs 2.4%, Fisher’s exact test, p < .001).  
In addition, on average, FND group participants had higher scores on the of the 
subscales of the TAS-20.  On the Describing Feelings subscale (TAS_DDF), the difference,      
-5.76, BCa 95% CI [-8.11, -3.41], was significant, t(69) = -5.18, p < .001, and represented an 
effect size of d = 1.30; on the Difficulty Identifying Feelings subscale (TAS_DIF), the 
difference, -10.85, BCa 95% CI [-14.42, -7.28], was significant, t(69) = -6.88, p < .001, and 
represented an effect size of d = 1.86; and on the Externally-Oriented Thinking subscale 
(TAS_EOT), the difference, -5.28, BCa 95% CI [-7.29, -3.30], was also significant, t(69) = -
5.19, p < .001 and represented an effect size of d = 1.32. 
In summary, Hypothesis i was fully supported, with the FND group participants 
having, on average, significantly higher scores on the TAS-20 and TAS-20 subscales, than 
control group participants, with large effect sizes in all cases. 
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Table 2.  
Group mean scores on the TAS-20 and TAS-20 subscales, RFQ Certainty about mental states 
subscale, RFQ Uncertainty about mental states subscale, PHQ-15 checklist, and Neuro 
checklist  
 FND group 
(n=29) 
Mean (SD) 
Control group 
(n=42) 
Mean (SD) 
TAS-20 Total  62.68 (14.24) 40.79 (10.61) 
TAS-20 Difficulty Describing Feelings (DDF) subscale 16.93 (4.84) 11.17 (4.45) 
TAS-20 Difficulty Identifying Feelings (DIF) subscale 24.68 (7.45) 13.83 (5.82) 
TAS-20 Externally Oriented Thinking (EOT) subscale 21.07 (4.57) 15.79 (3.99) 
   
RFQ Certainty about Mental States (RFQ_C) subscale 0.63 (0.72) 1.03 (0.62) 
RFQ Uncertainty about Mental States (RFQ_U) subscale 1.26 (0.82) 0.50 (0.43) 
        
PHQ-15 checklist 9.07 (3.41) 4.38 (2.78) 
Neuro checklist 4.62 (2.38) 0.48 (1.02) 
 
Hypothesis ii 
The second hypothesis was that FND group participants would be more prone to 
hypomentalizing than control participants, an impairment of reflective functioning 
characterised by low certainty about mental states (indicated by significantly lower scores on 
the RFQ_C subscale), and high uncertainty about mental states (indicated by significantly 
higher scores on the RFQ_U states subscale). 
The data supported both elements of this hypothesis.  On average, FND group 
participants had lower scores on the RFQ_C subscale, and the difference, 0.40, BCa 95% CI 
[0.05, 0.77], was significant, t(69) = 2.50, p = .015, representing an effect size of d = -0.65. 
FND group participants also, on average, had higher scores on RFQ_U subscale (indicating 
higher uncertainty about mental states), and this difference, -0.77, BCa 95% CI [-1.10, -0.48], 
was significant, t(38.90) = -4.64, p < .001, representing an effect size of d = 1.78.  This 
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pattern, of low certainty and high uncertainty about mental states, indicates significantly 
greater hypomentalizing in the FND group participants.  
   
Hypothesis iii 
The third hypothesis was that FND group participants would have more somatic and 
neurological symptoms of a generalized nature, than control group participants, as assessed 
by the PHQ-15 checklist and Neuro checklist.  
Consistent with the hypothesis, on average, FND group participants had higher scores 
on the PHQ15 checklist, and the difference, -4.69, BCa 95% CI [-6.06, -3.20], was 
significant, t(52.03) = -6.13, p < .001, representing an effect size of d = 1.69. FND group 
participants also, on average, had higher scores on the neurological symptoms checklist, and 
this difference, -4.14, BCa 95% CI [-5.03, -3.17], was also significant, t(35.13) = -8.83, p < 
.001, and represented an effect size of d = 4.07. 
   
Hypothesis iv 
The fourth hypothesis was that higher levels of alexithymia, and greater use of 
hypomentalizing, would predict FND (vs. control) group membership in a logistic regression, 
when depressive symptoms, anxiety symptoms, and educational attainment were controlled 
for.  Eight separate regression analyses were conducted, with PHQ-8, GAD-7, and 
educational attainment scores entered in step one of each model, and each of the eight 
predictors of interest (scores on the TAS_20_TOTAL, TAS_DDF, TAS_DIF, TAS_EOT, 
RFQ_C, RFQ_U, PHQ-15 checklist, and Neuro checklist) entered in step two.   
The results of the omnibus test of model coefficients were examined for each 
regression, with a significant improvement in model fit after the addition of the predictor 
variable of interest indicating that this variable was a significant contributor to the model, 
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above and beyond the effects of the covariates (Open University, 2009).  The full details of 
the regression analyses are presented in Appendix 12, with the key findings in Tables 3-10. 
When TAS-20 total score was added as a predictor to a logistic regression model that 
had previously just included the covariates as predictors, the model fit significantly improved 
(χ2(1) = 4.74, p = .03), indicating that alexthymia predicted group (FND vs. control) 
membership, over and above any effects of the covariates. The Neuro checklist was also 
predictive of group status after controlling for covariates (χ2(1) = 5.396, p = .02). However, 
the model fit was not significantly improved when the TAS_DDF, TAS_DIF, TAS_EOT, 
RFQ_C, RFQ_U or the PHQ-15 checklist scores were added to the logistic regression as the 
predictor of interest (all p > .05), indicating that these variables were not significant 
predictors, after controlling for confounding variables. 
 
Table 3. Logistic regression analysis for TAS-20 total score predicting FND group status 
(FND diagnosis present or absent), controlling for covariates (depressive symptoms, anxiety 
symptoms, and educational attainment) 
 B S.E. Wald df Sig. 
PHQ-8 .203 .143 2.028 1 .154 
GAD-7 -.075 .140 .288 1 .592 
Educational attainment -.703 .252 7.808 1 .005 
TAS_20_TOTAL .095 .048 3.967 1 .046 
Constant -2.824     
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Table 4. Logistic regression analysis for TAS_DDF score predicting FND group status (FND 
diagnosis present or absent), controlling for covariates (depressive symptoms, anxiety 
symptoms, and educational attainment) 
 B S.E. Wald df Sig. 
PHQ-8 .301 .142 4.516 1 .034 
GAD-7 -.118 .145 .662 1 .416 
Educational attainment -.758 .261 8.454 1 .004 
TAS_DDF .177 .109 2.612 1 .106 
Constant -.627     
 
Table 5. Logistic regression analysis for TAS_DIF score predicting FND group status (FND 
diagnosis present or absent), controlling for covariates (depressive symptoms, anxiety 
symptoms, and educational attainment) 
 B S.E. Wald df Sig. 
PHQ-8 .205 .159 1.656 1 .198 
GAD-7 -.063 .149 .180 1 .671 
Educational attainment -.744 .254 8.589 1 .003 
TAS_DIF .107 .080 1.778 1 .182 
Constant .144     
 
Table 6. Logistic regression analysis for TAS_EOT score predicting FND group status (FND 
diagnosis present or absent), controlling for covariates (depressive symptoms, anxiety 
symptoms, and educational attainment) 
 B S.E. Wald df Sig. 
PHQ-8 .288 .138 4.345 1 .037 
GAD-7 -.077 .136 .324 1 .569 
Educational attainment -.622 .251 6.169 1 .013 
TAS_EOT .194 .108 3.242 1 .072 
Constant -2.786     
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Table 7. Logistic regression analysis for RFQ_C score predicting FND group status (FND 
diagnosis present or absent), controlling for covariates (depressive symptoms, anxiety 
symptoms, and educational attainment) 
 B S.E. Wald df Sig. 
PHQ-8 .352 .152 5.340 1 .021 
GAD-7 -.087 .145 .357 1 .550 
Educational attainment -.782 .261 8.960 1 .003 
RFQ_C .630 .694 .824 1 .364 
Constant .664     
 
Table 8. Logistic regression analysis for RFQ_U score predicting FND group status (FND 
diagnosis present or absent), controlling for covariates (depressive symptoms, anxiety 
symptoms, and educational attainment) 
 B S.E. Wald df Sig. 
PHQ-8 .305 .150 4.160 1 .041 
GAD-7 -.095 .144 .436 1 .509 
Educational attainment -.738 .262 7.961 1 .005 
RFQ_U .166 .832 .040 1 .842 
Constant 1.328     
 
Table 9. Logistic regression analysis for PHQ-15 checklist score predicting FND group 
status (FND diagnosis present or absent), controlling for covariates (depressive symptoms, 
anxiety symptoms, and educational attainment) 
 B S.E. Wald df Sig. 
PHQ-8 .277 .173 2.567 1 .109 
GAD-7 -.083 .146 .322 1 .570 
Educational attainment -.756 .258 8.607 1 .003 
PHQ-15 checklist .071 .188 .144 1 .705 
Constant 1.257     
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Table 10. Logistic regression analysis for Neuro. checklist score predicting FND group 
status (FND diagnosis present or absent), controlling for covariates (depressive symptoms, 
anxiety symptoms, and educational attainment) 
 B S.E. Wald df Sig. 
PHQ-8 .151 .157 .920 1 .337 
GAD-7 -.110 .153 .516 1 .473 
Educational attainment -.558 .271 4.224 1 .040 
Neuro checklist .764 .470 2.642 1 .104 
Constant .503     
 
Hypothesis v 
In order to explore whether alexithymia and hypomentalizing would predict somatic 
and neurological symptoms of a more generalized nature, a series of linear regression 
analyses were undertaken on the whole sample (FND group and healthy control group 
participants), with TAS-20 total, RFQ_C, and RFQ_U scores as the independent variables, 
and the PHQ15 checklist and Neuro checklist scores as the dependent variables.   
The scatter-plots showed strong positive linear relationships between TAS-20 score 
and PHQ-15 checklist score, and between TAS-20 score and Neuro checklist score (Figure 
1).  This was confirmed with Pearson’s correlation coefficients of .66 and .67, respectively.  
The regression showed a significant relationship between TAS-20 score and PHQ-15 
checklist score (p < .001), with a slope coefficient for the TAS-20 of .16.  The R2 value was 
.440, indicating 44% of the variation in PHQ-15 checklist score can be explained by the 
model containing only TAS-20 score. The regression also showed a significant relationship 
between TAS-20 score and Neuro checklist score (p < .001), with a slope coefficient for the 
TAS-20 of .10.  The R2 value was .443, indicating 44.3% of the variation in PHQ-15 
checklist score can be explained by the model containing only the TAS-20 score.  
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Figure 1. TAS-20 score (TAS_20_TOTAL) as predictor of PHQ15 checklist 
(PHQ15_Checklist_TOT) and Neuro checklist (Neuro_TOT)  scores. 
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The scatter-plots showed strong negative linear relationships between RFQ_C score 
and PHQ-15 checklist score, and between RFQ_C score and Neuro checklist score (Figure 2).  
This was confirmed with Pearson’s correlation coefficients of -.48 and -.43, respectively.  
The regression showed a significant relationship between RFQ_C score and PHQ-15 
checklist score (p < .001), with a slope coefficient for the RFQ_C of -2.69.  The R2 value was 
.234, indicating 23.4% of the variation in PHQ-15 checklist score can be explained by the 
model containing only RFQ_C score.  The regression also showed a significant relationship 
between RFQ_C score and PHQ-15 checklist score (p < .001), with a slope coefficient for the 
RFQ_C of -1.68.  The R2 value was .187, indicating 18.7% of the variation in Neuro checklist 
score can be explained by the model containing only the RFQ_C score.  
As hypothesised, in contrast to the RFQ_C, strong positive linear relationships 
between RFQ_U score and PHQ-15 checklist score, and between RFQ_U score and Neuro 
checklist score, were shown by this scatterplots (Figure 3).  This was confirmed with 
Pearson’s correlation coefficients of .58 and .61, respectively.  The regression showed a 
significant relationship between RFQ_U score and PHQ-15 checklist score (p < .001), with a 
slope coefficient for the RFQ_U of 3.07.  The R2 value was .336, indicating 33.6% of the 
variation in PHQ-15 checklist score can be explained by the model containing only RFQ_U 
score.  The regression also showed a significant relationship between RFQ_U score and 
Neuro checklist score (p < .001), with a slope coefficient for the TAS-20 of 2.26.  The R2 
value was .373, indicating 37.3% of the variation in Neuro checklist score can be explained 
by the model containing only the RFQ_U score.  
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Figure 2. RFQ Certainty about mental states score (RFQ_C) as predictor of PHQ15 checklist 
(PHQ15_Checklist_TOT) and Neuro checklist (Neuro_TOT) scores. 
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Figure 3. RFQ Uncertainty about mental states score (RFQ_U) as predictor of PHQ15 
checklist (PHQ15_Checklist_TOT) and Neuro checklist (Neuro_TOT) scores.  
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In summary, Hypothesis v was fully supported by the data – higher scores on the 
PHQ-15 checklist and Neuro checklist (indicating somatic and neurological symptoms of a 
generalized nature) were associated with higher scores on the TAS-20 (indicating higher 
alexithymic traits), lower scores on the RFQ_C, and higher scores on the RFQ_U (indicating 
greater tendency to hypomentalize).  
 
Discussion 
 
The aim of this study was to investigate if alexithymia and impairments in 
mentalization were more common in people with FND than in control participants, and 
furthermore, to investigate whether such difficulties would also be predictive of somatic and 
neurological symptoms of a more generalized nature. 
The mean total and subscales scores of the TAS-20 were significantly higher in the 
FND group than in the control group, suggesting that difficulties with identifying and 
describing feelings, and externally-oriented thinking, are significant issues for people with 
FND.  These findings are consistent with previous studies of alexithymic traits in people with 
functional seizures (Kaplan et al., 2013; Urbanek, Harvey, McGowan, & Agrawal, 2014; 
Novakova, Howlett, Baker, & Reuber, 2015) and with functional motor/sensory symptoms 
(Demartini et al., 2014; Steffen, Fiess, Schmidt & Rockstroh, 2015; Kienle et al., 2017).  
This, however, was the first study to explore alexithymia in this type of FND sample (with 
mixed symptoms), typically seen in UK neuropsychiatry/neuropsychology services.  The 
proportion of the FND group scoring above the clinical cut-off for alexithymia in this study 
(55.2%) was higher than the proportions reported in recent studies of groups of people with 
functional motor symptoms (34.5%: Demartini et al., 2014), and in some of the studies of 
functional seizures (40.4%: Kaplan et al., 2013; 31%: Wolf et al., 2015), though not all (63%; 
Urbanek et al., 2014).  This finding, along with the finding that the mean score of the entire 
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FND group on the TAS-20 was above the recommended clinical cut-off for the measure (≥ 
61), highlights that these findings have clinical, as well as statistical, significance.     
Total alexithymia score was also predictive of FND (versus control group) status  
after controlling for group differences in depressive and anxiety symptoms, and educational 
attainment, suggesting that group differences in alexithymia were not attributable to these 
covariates alone.  Although the subscales were no longer predictive of group status after 
controlling for covariates, the p values of the Difficulty Describing Feelings (p = .093) and 
Externally Oriented Thinking (p = .057) subscales were approaching significance, possibly 
indicating a Type II error due to insufficient power.   
These results, along with the more clear-cut absence of significant between-group 
differences on the Difficulty Identifying Feelings subscale (p = .182) may also be 
informative, however. A lack of difficulty with identifying feelings, coupled with impairment 
in describing feelings, and greater use of externally oriented thinking, may suggest that 
people with FND are more likely to have Type II alexithymia.  Type II alexithymia has been 
defined by Larsen, Brand, Bermond, and Hijman (2003) as being characterised by selective 
deficits in emotional cognition, but with a sparing of emotional experience (i.e. people feel 
the emotions, but have difficulty cognitively understanding them).  Higher prevalence of 
Type II alexithymia has previously been reported to be predictive of somatization in a general 
population study (Bailey & Henry, 2007).  The findings of this study suggest that this may be 
an area that warrants further research in people with FND too.  
Regarding reflective functioning, there were significant between-group differences on 
both subscales of the RFQ, suggesting that people with FND do experience the absence of 
normal certainty about mental states that is characteristic of hypomentalizing.  It has been 
hypothesised that the absence of an adaptive level of certainty about one’s own and others’ 
mental states may characterize people who are more prone to using affective coping 
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strategies, rather than cognitive coping strategies, to regulate the emotional arousal induced 
by everyday events (Badoud et al., 2015). A plausible mechanism for the development of 
functional symptoms may therefore be that people with FND are more likely to be reliant on 
affective coping strategies to manage arousal, but these affective strategies are also being 
influenced by alexithymic traits, with a consequence of them being ‘converted’ in to physical 
symptoms.  The measures of alexithymia and hypomentalization in this study were highly 
correlated, so this particular hypothesis was not explored further, but it may be worth 
investigating in future research. 
The results from the RFQ should also be interpreted with the caveat that neither 
subscale was predictive of FND status after controlling for covariates.  This may indicate that 
hypomentalizing is more associated with comorbid affective symptoms and/or lower 
educational attainment. Alternatively, the study was only powered to find differences with a 
large effect size, and the use of a brief screening measure of reflective functioning may not 
have been sufficient to detect group differences. A more comprehensive measure of reflective 
functioning may have more sensitivity to detect differences in hypomentalizing, and the 
findings of this study offer support for further research in this area. 
The nature of the symptoms (i.e. seizures, motor symptoms, or sensory symptoms) 
experienced by participants with FND in this study were not evaluated.  This was partly 
because the clinical records of the recruiting services did not consistently record this 
information – diagnosis was typically recorded as FND when the American Psychiatric 
Association diagnostic criteria (APA, 2013) were used, or dissociative disorder when the 
World Health Organisation diagnostic criteria (WHO, 1990) were preferred.  It was also 
partly because comorbidity with other functional and organic symptoms was so common 
among service users of the recruiting teams.  As a result, the findings of this study cannot 
directly inform Kanaan et al.’s (2017) recent theory (described in the Introduction section), 
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that there may be etiological differences between functional symptoms that are acute (e.g. 
seizures) and those that are continuous or chronic (e.g. motor paralyses).  According to the 
measures used in this study, many individual participants within the FND group had 
significant difficulties with alexithymia and/or hypomentalizating – an interesting area for 
future research may be to explore whether particular patterns of impairment (e.g. high 
alexithymia and high hypomentalization vs high alexithymia and low hypomentalization) are 
more strongly associated with particular functional symptom profiles (acute vs chronic), 
particular types of adverse childhood experiences (e.g. emotional neglect/abuse vs sexual 
abuse), or another unrelated variable (or variables).    
Finally, the results of the linear regression analyses support a hypothesis that 
alexithymia and hypomentalizing increase vulnerability to experiencing somatic symptoms, 
and suggest that this mechanism may not be unique to people with FND.  While links 
between alexithymia and other somatization disorders have previously been described (De 
Gucht & Heiser, 2003), this study is the first to show that that hypomentalization is predictive 
of experiencing more somatic and neurological symptoms.  However, these linear regressions 
were bivariate, and did not control for symptoms of anxiety and depression, or for 
educational attainment.  These confounding variables could, therefore, potentially be more 
significant predictors of the higher reported somatic and neurological symptoms, than 
alexithymia or hypomentalizing.  Further research, where these variables are held constant in 
the analyses (and preferably with larger sample sizes to increase power) would be necessary 
before definite conclusions on this hypothesis could be drawn. 
 
Limitations 
A number of other methodological issues should also be kept in mind in the 
interpretation of these findings. 
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Firstly, participants in both groups took part on a voluntary basis.  This raises the 
potential for self-selection bias, particularly as people who find this challenging or 
uncomfortable to think about emotions or their own/others’ mental states may have been less 
likely to volunteer to take part in the study. As a result, scores on the measures of alexithymia 
and mentalization may not be an accurate representation of the true population values. 
Secondly, FND group participants were all active service users of NHS 
neuropsychiatry services.  The study did not assess where in their treatment participants were 
(e.g. waiting for a formal assessment vs being monitored following successful treatment), and 
it is plausible that alexithymic traits or hypomentalizing may be improved by engagement in 
psychological treatment (Lumley, Neely, & Burger, 2007). 
Thirdly, the FND group participants were highly heterogeneous, with a variety of 
symptom presentations.  Participants with a comorbid neurological problem (‘functional 
overlay’) were also included.  Previous research on FND has tended to focus on specific 
symptoms profiles, and some might argue that this FND sample was too heterogeneous 
varied to make useful findings.  However, heterogeneity and complexity of symptoms is 
widely acknowledged to be the norm rather than the exception in FND (Şar, Akyüz, 
Kundakçi, Kiziltan, & Doğan, 2004), and the service users invited to participate in this study 
were representative of typical NHS neuropsychiatry service users, increasing the external 
validity of the findings. 
Fourthly, there were significant differences between the FND and control groups on 
measures of educational attainment and ethnicity.  Educational attainment was controlled for 
statistically in the analyses, but this was not possible with ethnicity (due to the small number 
of participants in categories other than White), and this may have been an additional 
confounding variable.   
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Finally, this study did not include a measure of childhood abuse/neglect, and therefore 
does not explicitly implicate such experiences in the subsequent development of alexithymia 
and/or hypomentalization.  An alternative explanation may be that 
alexithymia/hypomentalization are indicative of a neurodevelopmental condition, such as 
autism (e.g. a case study reported by Miyawaki et al., 2016).  This is an area of research in 
FND that appears to have been largely overlooked, and may warrant further exploration.    
 
Clinical implications  
This study illustrates that alexithymic traits appear to be the norm, rather than the 
exception, for people with FND.  Using a relatively quick measure of alexithymia such as the 
TAS-20 may provide helpful information in the assessment and treatment planning stages, 
and guidance as to whether a person may engage better with therapies focusing on insight and 
emotional awareness, more structured cognitive-behavioural approaches (Lumley et al., 
2006), or treatments with a primary focus on physical rehabilitation (McKee et al., 2018).  
The findings regarding alexithymia and reflective functioning also suggest that treatment 
approaches that specifically include a focus on affect recognition and management may be 
helpful for people with FND, such as mentalization-based cognitive therapy or dialectical-
behaviour therapy (e.g. the DBT-informed treatment for functional seizures, recently 
described by Bullock, Mirza, Forte, & Trockel, 2015).    
Equally, however, the findings of this study are based on mean group scores, and 
several of the FND group participants scored well within the normal range on the measures of 
alexithymia and reflective functioning.  A “one size fits all” approach to FND seems highly 
unlikely given the heterogeneity and complexity of symptoms, and the retention and 
expansion of multi-disciplinary, individualised, formulation-based approaches (such as those 
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proposed in the Joint Commissioning Panel for Mental Health guidance, 2017) appears 
essential. 
Conclusion 
This study has highlighted that difficulties with identifying and describing feelings, 
and with uncertainty about their own and others’ minds, appear to be common experiences 
for people with FND.  These difficulties may contribute to a tendency to express distress via 
neurological or physical symptoms, and make understanding and accepting this idiosyncratic 
coping mechanism challenging.  The findings of this study suggest that further exploration of 
these factors may lead to the development of a more comprehensive theoretical model of 
FND in future, and more importantly, may help professionals and others working with people 
with FND to better understand their difficulties, and to offer support that is more engaging 
and helpful.  
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Appendix 8 
 
FND group Participant Information Sheet 
 
 
Participant Information Sheet 
Hello. My name is Garret Coy and I am a trainee clinical psychologist at Canterbury 
Christ Church University.  I would like to invite you to take part in a research study, 
which I am undertaking as part of the requirement of the Doctoral Programme in 
Clinical Psychology.  
Before you decide, it is important that you understand why the research is being done 
and what it would involve for you. You can talk to your family, friends, psychologist or 
doctors about this study if you want to. 
 
Part 1 of this information sheet tells you the purpose of this study and what will happen 
to you if you take part.  
 
Part 2 gives you more detailed information about the conduct of the study. 
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Part 1 
Formal study details: 
Title of Project:  Emotional awareness, mentalization, and symptom complexity in 
functional neurological symptom disorder (FND) 
Name of Researcher: Garret Coy 
IRAS Project ID: 211216 
 
What is the purpose of the research study? 
The broad aim of this study is to explore how people diagnosed with functional 
neurological disorder (FND) think about their emotions and problems with the physical 
health.  Functional Neurological Disorder (FND) encompasses a diverse range of 
symptoms, including functional limb weakness and movement disorders, functional and 
dissociative attacks (non epileptic), sensory problems, cognitive problems, visual and 
speech symptoms. The symptoms may appear similar to neurological diseases, 
including those of multiple sclerosis, Parkinson’s and epilepsy, and can be just as 
debilitating, but are not caused by structural disease of the nervous system, and rather 
appear to arise from a problem with the “functioning” of the nervous system.  Further 
information about FND is available at www.fndaction.org.uk .  
It is hoped that this study will lead to greater knowledge and understanding of the 
condition, and potentially to improved treatments for people with FND. 
 
Why have I been invited to take part? 
You have been invited to take part because you have a diagnosis of functional 
neurological disorder (FND), and are a service user of the Neuropsychiatry Service at 
XXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXX 
XXXXXXXXXXXXXXXX In total, 52 participants will take part in this study. 
 
Do I have to take part? 
It is your choice whether to take part in the study or not, and your access to treatment 
will not be affected in any way if you do not wish to take part in the study.  If you decide 
to participate, you may withdraw your consent to further involvement in the research at 
any time without giving a reason. 
 
What will happen if I decide to take part? 
If you decide to take part, you will be asked to complete the consent form and six 
multiple-choice questionnaires, with questions about your basic details, and questions 
looking at the different ways that people experience and manage emotions and physical 
health problems.  There are also some optional questions about your experience of 
taking part in the study, and your response to these questions will be shared with the 
service user group, the Salomon’s Advisory Group of Experts by Experience (SAGE).  It 
should take approximately 30-60 minutes to complete all of the questionnaires.  The 
questionnaires are included with this letter, and can be completed and returned in the 
post to the address below or in person to your SLaM/KMPT Neuropsychiatry clinic, or 
can be completed in the clinic during your next appointment.  The questionnaires can 
also be completed online at www.qualtrics.com/websitelinkTBC.   
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What are the possible disadvantages of taking part? 
Some people might find that answering questions regarding their experiences of some 
emotions, or of ways of managing them, may cause some distress or discomfort.  If you 
experience any distress, you are welcome to discuss this with your clinician at the 
XXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXX.  There is also support available to anyone 
experiencing distress at any time from The Samaritans, who can be contacted at any 
time by calling 116 123, or visiting their website at www.samaritans.org.  If you find it 
too difficult and upsetting to complete the questionnaires, you can stop at any time. 
 
What are the benefits of taking part? 
Your participation will help us to better understand functional neurological symptoms, 
and the processes that could be contributing to these symptoms.  The findings might 
lead to further research in the area and even the development of better treatments for 
the problem.  There is an option at the end of the questionnaires to leave your contact 
details if you would like to receive a summary of the findings of the study after it is 
completed. 
To thank you for your time, you will also receive a £10 Amazon gift voucher, if you wish. 
 
What if there is a problem? 
Any complaint about the way you have been dealt with during the study or any possible 
harm you might suffer will be addressed. The detailed information on this is given in 
Part 2. 
 
Will my participation in this study be kept confidential? 
Yes. We will follow ethical and legal practice and all information about you will be 
handled in confidence. The details are included in Part 2. 
 
 
 
 
 
 
If the information in Part 1 has interested you and you are considering 
participation, please read the additional information in Part 2 before making any 
decision. 
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Part 2 
 
Will my participation in this study be kept confidential? 
All data and personal information will be stored securely within NHS and Canterbury Christ 
Church University premises, in accordance with the Data Protection Act 1998 and the 
University’s own data protection requirements.  All information collected about you during 
the course of the research will be kept strictly confidential, and data will be stored securely 
on a CD in a locked cabinet. Your answers will not be linked directly to your name. Data can 
only be accessed by the principal researcher and the supervisors, listed in the next section. 
The collected data will be used for statistical analysis, the results of which might be 
published in the future. You will, however, not be identified in any publication. The study 
documents and data will be disposed of securely after five years, and any documents or 
electronic files containing personal identifiable information (i.e. your email address) will be 
destroyed immediately after completion of the study. If you are interested in a summary of 
findings of this research, please let me know by ticking the box at the end of the consent 
form, and providing an email address to send the findings to. 
 
Will anyone else be told I am participating in the study? 
Your consultant at the XXXXXXXXXXXXXXXX Neuropsychiatry service will be informed that 
you have participated in the study, for their records.  They will only be informed that you 
have participated, and none of your responses will be shared with them. 
 
Who is organising and funding the research? 
This research project is being undertaken as part of the requirement of a Doctoral 
Programme in Clinical Psychology at Canterbury Christ Church University, with the 
following people involved: 
- Principal Investigator: Garret Coy, trainee clinical psychologist, Canterbury Christ 
Church University 
- Lead research supervisor: XXXXXXXXXXX, (Canterbury Christ Church University)  
- Clinical supervisor: XXXXXXXXXXXXXXXX (XXXXXXXXXXXXXXXX 
XXXXXXXXXXXXXXXX) 
- Research consultant: XXXXXXXXXXXXXXXX (XXXXXXXXXXXXXXXX 
XXXXXXXXXXXXXXXX).   
This project is funded by Canterbury Christ Church University. 
 
Who has reviewed the study? 
All research in the NHS is looked at by independent group of people, called a Research 
Ethics Committee, to protect your safety and well-being. This study has been reviewed and 
given favourable opinion by the NHS Ethics Committee. 
 
Who do I contact if I need more information? 
If there is anything that is not clear, or if you would like more information regarding this 
study, please feel free to contact me by leaving a message for me on a 24-hour voicemail 
phone line at 0333 011 7070. Please say that the message is for me [Garret Coy] and leave a 
contact number so that I can get back to you. You can also email me at 
g.coy262@canterbury.ac.uk. 
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What will happen if I don’t want to carry on with the study? 
If you wish to withdraw from the study at any time, please contact me by leaving a message 
on a 24-hour voicemail phone line at 0333 011 7070. Please say that the message is for me 
[Garret Coy] and leave a contact number so that I can get back to you. You can also email me 
at g.coy262@canterbury.ac.uk. 
 
What if there is a problem? 
If you have a concern about any aspect of this study, please contact me and I will do my best 
to answer your questions (g.coy262@canterbury.ac.uk or 0333 011 7070). If you remain 
unhappy and wish to complain formally, you can do this by contacting Professor Paul Camic, 
Research Director on 0333 011 7114. 
 
You can also contact the Patient Advice and Liaison Service (PALS), who offer confidential 
advice, support and information on health-related matters. They provide a point of contact 
for patients, their families and their carers.  They can be contacted on: 
XXXX Service Users –  Email:  XXXXXXXXXXXXXXXX 
Phone:  XXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXX 
XXXXXXXXXXXXXXXX  
XXXX Service Users –  Email:  XXXXXXXXXXXXXXXX 
Phone:  XXXXXXXXXXXXXXXX 
 
Further information about taking part in NHS research is also available on the NHS Choices 
website, at http://www.nhs.uk/Conditions/Clinical-trials/Pages/Introduction.aspx . 
 
What if I want to take part? 
If you have now decided that you want to take part in the study, thank you!  I hope that you 
will find it to be an interesting experience.   
To take part, please read and sign the enclosed consent form, and then complete the 
questionnaires and bring them to your next appointment at the XXXXXXXXXXXXXXXX 
Neuropsychiatry clinic, or return them by post to: 
XXXXXXXXXXXXXXXX 
XXXXXXXXXXXXXXXX 
XXXXXXXXXXXXXXXX 
XXXXXXXXXXXXXXXX 
XXXXXXXXXXXXXXXX 
XXXXXXXXXXXXXXXX 
XXXXXXXXXXXXXXXX 
XXXXXXXXXXXXXXXX 
XXXXXXXXXXXXXXXX 
 
You can also complete the questionnaires online by visiting 
www.tinyurl.com/FNDStudy17GC and using the following unique ID code when prompted: 
……………………………………………………………….. 
Don’t forget – If you wish to receive the £10 Amazon gift voucher, please tick the relevant 
box on the consent form and provide an email address where the voucher can be sent. 
 
Thank you for considering your participation in this study. 
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Office use only: 
 
Date received: 
Participant ID: 
Appendix 9 
 
FND group consent form 
 
 
CONSENT FORM 
  
Title of Project:  Emotional awareness, mentalization, and symptom complexity in 
functional neurological symptom disorder (FND) 
Name of Researcher: Garret Coy 
IRAS Project ID: 211216 
 
Please tick box 
MANDATORY Questions (Required for participation in the study)  
 
1. I confirm that I have read and understand the Participant Information Sheet, 
dated 21/7/17 (Version 5), for the above study. I have had the opportunity to 
consider the information, ask questions and have had these answered 
satisfactorily.  
  
2. I understand that my participation is voluntary and that I am free to withdraw 
at any time without giving any reason, without my medical care or legal rights 
being affected.   
  
3. I understand that relevant sections of data collected during the study may be 
looked at by the lead supervisors, XXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXX 
and XXXXXXXXXXXXXXXX.  I give permission for these individuals to have access 
to my data.   
 
4. I agree to my consultant in the XXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXX 
service being informed of my participation in the study.   
  
5. I agree to take part in the above study.  
  
 
Name of Participant_________________________________________           Date________________  
 
Signature _________________________________________________ 
 
 
 
Name of Person taking consent (if applicable) ____________________           Date_______________  
 
Signature __________________________________________________ 
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Please tick box 
OPTIONAL Questions (Not required for participation in the study) 
 
1. I wish to provide feedback about my experience of taking part in the study, 
and agree for direct quotes from my feedback to be shared anonymously with 
the service user group, the Salomon’s Group of Experts by Experience (SAGE). 
 
2. I wish to receive a £10 Amazon e-voucher to thank me for the time I spent 
taking part in the study. 
 
3. I wish to receive a summary of the results of the study, once it has been 
completed. 
 
 
If you have ticked the box corresponding to OPTIONAL Questions 2 or 3 above, please  
provide an email address where you can be contacted with your e-voucher and/or the  
summary of the results of the study*:  
__________________________________________________________________________ 
 
 
Name of Participant_________________________________________           Date________________  
 
Signature _________________________________________________ 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*In accordance with the Data Protection Act, the email address provided will be used only 
for the purposes for which consent has been provided, and will not be stored after 
completion of the study.  
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Appendix 10 
 
Control group Participant Information Sheet 
 
 
Participant Information Sheet 
Hello. My name is Garret Coy and I am a trainee clinical psychologist at Canterbury 
Christ Church University.  I would like to invite you to take part in a research study, 
which I am undertaking as part of the requirement of the Doctoral Programme in 
Clinical Psychology.  
Before you decide, it is important that you understand why the research is being done 
and what it would involve for you. You can talk to your family, friends, psychologist or 
doctors about this study if you want to. 
 
Part 1 of this information sheet tells you the purpose of this study and what will happen 
to you if you take part.  
Part 2 gives you more detailed information about the conduct of the study. 
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Part 1 
Formal study details: 
Title of Project:  Emotional awareness, mentalization, and symptom complexity in 
functional neurological symptom disorder (FND) 
Name of Researcher: Garret Coy 
IRAS Project ID: 211216 
 
What is the purpose of the research study? 
The broad aim of this study is to explore how people diagnosed with functional 
neurological disorder (FND) think about their emotions and problems with the physical 
health.  Functional Neurological Disorder (FND) encompasses a diverse range of 
symptoms, including functional limb weakness and movement disorders, functional and 
dissociative attacks (non epileptic), sensory problems, cognitive problems, visual and 
speech symptoms. The symptoms may appear similar to neurological diseases, 
including those of multiple sclerosis, Parkinson’s and epilepsy, and can be just as 
debilitating, but are not caused by structural disease of the nervous system, and rather 
appear to arise from a problem with the “functioning” of the nervous system.  Further 
information about FND is available at www.fndaction.org.uk .  
It is hoped that this study will lead to greater knowledge and understanding of the 
condition, and potentially to improved treatments for people with FND. 
 
Why have I been invited to take part? 
You have been chosen to take part to form part of the control group, against whom we 
will compare the results of the group of people with FND.  In total, 52 participants will 
take part in this study. 
 
Do I have to take part? 
It is your choice whether to take part in the study or not.  If you decide to participate, 
you may withdraw your consent to further involvement in the research at any time 
without giving a reason.  
 
What will happen if I decide to take part? 
If you decide to take part, you will be asked to complete the consent form and six 
multiple-choice questionnaires, with questions about your basic details, and questions 
looking at the different ways that people experience and manage emotions and physical 
health problems.  There are also some optional questions about your experience of 
taking part in the study, and your response to these questions will be shared with the 
service user group, the Salomon’s Advisory Group of Experts by Experience (SAGE).  It 
should take approximately 30-60 minutes to complete all of the questionnaires.   
The questionnaires can all be completed online by following this link: 
www.qualtrics.com/FNDstudyGC18 
 
What are the possible disadvantages of taking part? 
Some people might find that answering questions regarding their experiences of some 
emotions, or of ways of managing them, may cause some distress or discomfort.  There 
is support available to anyone experiencing distress at any time from The Samaritans, 
who can be contacted at any time by calling 116 123, or visiting their website at 
www.samaritans.org.  If you find it too difficult and upsetting to complete the 
questionnaires, you can stop at any time. 
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What are the benefits of taking part? 
Your participation will help us to better understand functional neurological symptoms, 
and the processes that could be contributing to these symptoms.  The findings might 
lead to further research in the area and even the development of better treatments for 
the problem.  There is an option at the end of the questionnaires to leave your contact 
details if you would like to receive a summary of the findings of the study after it is 
completed. 
To thank you for your time, you can also be entered in to a prize draw to win one of two 
Amazon gift vouchers, worth £25 or £10, if you wish. 
 
What if there is a problem? 
Any complaint about the way you have been dealt with during the study or any possible 
harm you might suffer will be addressed. The detailed information on this is given in 
Part 2. 
 
Will my participation in this study be kept confidential? 
Yes. We will follow ethical and legal practice and all information about you will be 
handled in confidence. The details are included in Part 2. 
 
 
 
 
 
 
If the information in Part 1 has interested you and you are considering 
participation, please read the additional information in Part 2 before making any 
decision. 
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Part 2 
 
Will my participation in this study be kept confidential? 
All data and personal information will be stored securely within NHS and Canterbury 
Christ Church University premises, in accordance with the Data Protection Act 1998 and 
the University’s own data protection requirements.  All information collected about you 
during the course of the research will be kept strictly confidential, and data will be 
stored securely on a CD in a locked cabinet. Your answers will not be linked directly to 
your name. Data can only be accessed by the principal researcher and the supervisors, 
listed in the next section. The collected data will be used for statistical analysis, the 
results of which might be published in the future. You will, however, not be identified in 
any publication. The study documents and data will be disposed of securely after five 
years, and any documents or electronic files containing personal identifiable 
information (i.e. your email address) will be destroyed immediately after completion of 
the study. If you are interested in a summary of findings of this research, please let me 
know by ticking the box at the end of the consent form, and providing an email address 
to send the findings to. 
 
Who is organising and funding the research? 
This research project is being undertaken as part of the requirement of a Doctoral 
Programme in Clinical Psychology at Canterbury Christ Church University, with the 
following people involved: 
- Principal Investigator: Garret Coy, trainee clinical psychologist, Canterbury 
Christ Church University 
- Lead research supervisor: XXXXXXXXXXXXXXXX (Canterbury Christ Church 
University)  
- Clinical supervisor: XXXXXXXXXXXXXXXX (XXXXXXXXXXXXXXXX 
XXXXXXXXXXXXXXXX) 
- Research consultant: XXXXXXXXXXXXXXXX (XXXXXXXXXXXXXXXX 
XXXXXXXXXXXXXXXX).   
This project is funded by Canterbury Christ Church University. 
 
Who has reviewed the study? 
All research in the NHS is looked at by independent group of people, called a Research 
Ethics Committee, to protect your safety and well-being. This study has been reviewed 
and given favourable opinion by the NHS Ethics Committee. 
 
Who do I contact if I need more information? 
If there is anything that is not clear, or if you would like more information regarding this 
study, please feel free to contact me by leaving a message for me on a 24-hour voicemail 
phone line at 0333 011 7070. Please say that the message is for me [Garret Coy] and 
leave a contact number so that I can get back to you. You can also email me at 
g.coy262@canterbury.ac.uk. 
 
What will happen if I don’t want to carry on with the study? 
If you wish to withdraw from the study at any time, please contact me by leaving a 
message on a 24-hour voicemail phone line at 0333 011 7070. Please say that the 
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message is for me [Garret Coy] and leave a contact number so that I can get back to you. 
You can also email me at g.coy262@canterbury.ac.uk. 
 
What if there is a problem? 
If you have a concern about any aspect of this study, please contact me and I will do my 
best to answer your questions (g.coy262@canterbury.ac.uk or 0333 011 7070). If you 
remain unhappy and wish to complain formally, you can do this by contacting Professor 
Paul Camic, Research Director on 0333 011 7114. 
You can also contact the Patient Advice and Liaison Service (PALS), who offer 
confidential advice, support and information on health-related matters. They provide a 
point of contact for patients, their families and their carers.  They can be contacted on: 
XXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXX;  
XXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXX 
XXXXXXXXXXXXXXXX  
XXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXX 
XXXXXXXXXXXXXXXX  
Further information about taking part in NHS research is also available on the NHS 
Choices website, at http://www.nhs.uk/Conditions/Clinical-
trials/Pages/Introduction.aspx . 
 
What if I want to take part? 
If you have now decided that you want to take part in the study, thank you!  I hope that 
you will find it to be an interesting experience.   
To take part, please read and agree to the electronic consent form, and then complete 
the online questionnaires, by visiting www.qualtrics.com/FNDstudyGC18 
 
Don’t forget - If you wish to enter the prize draw to win an Amazon voucher, please tick 
the relevant box on the consent form and provide an email address where you can be 
contacted about the outcome of the prize draw.   
 
 
Thank you for considering your participation in this study. 
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Office use only: 
 
Date received: 
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Appendix 11 
 
Control group consent form 
 
 
CONSENT FORM  
 
Title of Project:  Emotional awareness, mentalization, and symptom complexity in 
functional neurological symptom disorder (FND) 
Name of Researcher: Garret Coy 
IRAS Project ID: 211216 
Please tick box 
MANDATORY Questions (Required for participation in the study)  
  
1. I confirm that I have read and understand the Participant Information Sheet, 
dated 21/7/17 (Version 5), for the above study. I have had the opportunity to 
consider the information, ask questions and have had these answered 
satisfactorily.  
  
2. I understand that my participation is voluntary and that I am free to withdraw 
at any time without giving any reason, without my medical care or legal rights 
being affected.   
  
3. I understand that relevant sections of data collected during the study may be 
looked at by the lead supervisors, XXXXXXXXXXXXXXXXXXXXXXXXX, and 
XXXXXXXXXXXXXXXX.  I give permission for these individuals to have access to 
my data.    
  
4. I agree to take part in the above study.  
  
Name of Participant_________________________________________           Date________________  
 
Signature _________________________________________________ 
 
 
Name of Person taking consent (if applicable) _____________________           Date_______________  
 
Signature __________________________________________________ 
 
 
 
 
NOTE:  Consent for Control Group participants will be obtained via the online 
questionnaire, so this form is intended only to be representative of the questions and 
information that will comprise that form. 
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Please tick box 
OPTIONAL Questions (Not required for participation in the study) 
 
1. I wish to provide feedback about my experience of taking part in the study, 
and agree for direct quotes from my feedback to be shared anonymously with 
the service user group, the Salomon’s Group of Experts by Experience (SAGE). 
 
2. I wish to enter the prize draw to win a £25 or £10 Amazon e-voucher to 
thank me for the time I spent taking part in the study. 
 
3. I wish to receive a summary of the results of the study, once it has been completed. 
 
 
If you have ticked the box corresponding to OPTIONAL Questions 2 or 3 above, please  
provide an email address where you can be contacted with the results of the prize draw 
for  
the Amazon e-voucher, and/or the summary of the results of the study*:  
__________________________________________________________________________ 
 
 
Name of Participant_________________________________________           Date________________  
 
Signature _________________________________________________ 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*In accordance with the Data Protection Act, the email address provided will be used only 
for the purposes for which consent has been provided, and will not be stored after 
completion of the study.  
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Appendix 12 
 
Binary logistic regression SPSS outputs 
 
 
Block 0: Beginning Block 
 
Variables not in the Equation 
 Score df Sig. 
Step 0 Variable
s 
PHQ8_TOT 32.884 1 .000 
GAD7_TOT 22.491 1 .000 
Highest educational 
qualification 
25.950 1 .000 
Overall Statistics 39.664 3 .000 
 
 
Block 1: Method = Enter 
 
Omnibus Tests of Model 
Coefficients 
 
Chi-
square df Sig. 
Step 1 Step 48.991 3 .000 
Block 48.991 3 .000 
Model 48.991 3 .000 
 
 
Variables in the Equation 
 B S.E. Wald df Sig. Exp(B) 
95% C.I.for 
EXP(B) 
Lower Upper 
Step 
1a 
PHQ8_TOT .316 .141 5.046 1 .025 1.371 1.041 1.807 
GAD7_TOT -.094 .143 .429 1 .512 .910 .688 1.205 
Highest 
educational 
qualification 
-.747 .257 8.421 1 .004 .474 .286 .785 
Constant 1.401 1.476 .901 1 .343 4.059   
a. Variable(s) entered on step 1: PHQ8_TOT, GAD7_TOT, Highest educational 
qualification. 
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Logistic regression analysis for TAS-20 total score predicting FND group status (FND 
diagnosis present or absent), controlling for covariates (depressive symptoms, anxiety 
symptoms, and educational attainment) 
 
Block 2: Method = Enter 
 
Omnibus Tests of Model 
Coefficients 
 
Chi-
square df Sig. 
Step 1 Step 4.735 1 .030 
Block 4.735 1 .030 
Model 53.727 4 .000 
 
Variables in the Equation 
 B S.E. Wald df Sig. Exp(B) 
95% C.I.for 
EXP(B) 
Lower Upper 
Step 
1a 
PHQ8_TOT .203 .143 2.028 1 .154 1.225 .926 1.621 
GAD7_TOT -.075 .140 .288 1 .592 .927 .704 1.221 
Highest 
educational 
qualification 
-.703 .252 7.808 1 .005 .495 .302 .811 
TAS_20_TOTAL .095 .048 3.967 1 .046 1.100 1.002 1.208 
Constant -
2.824 
2.428 1.353 1 .245 .059 
  
a. Variable(s) entered on step 1: TAS_20_TOTAL. 
 
Logistic regression analysis for TAS_DDF score predicting FND group status (FND 
diagnosis present or absent), controlling for covariates (depressive symptoms, anxiety 
symptoms, and educational attainment) 
 
Block 2: Method = Enter 
 
Omnibus Tests of Model 
Coefficients 
 
Chi-
square df Sig. 
Step 1 Step 2.823 1 .093 
Block 2.823 1 .093 
Model 51.814 4 .000 
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Variables in the Equation 
 B S.E. Wald df Sig. Exp(B) 
95% C.I.for 
EXP(B) 
Lower Upper 
Step 
1a 
PHQ8_TOT .301 .142 4.516 1 .034 1.351 1.024 1.784 
GAD7_TOT -.118 .145 .662 1 .416 .889 .670 1.180 
Highest 
educational 
qualification 
-.758 .261 8.454 1 .004 .468 .281 .781 
TAS_DDF .177 .109 2.612 1 .106 1.193 .963 1.478 
Constant -.627 1.852 .115 1 .735 .534   
a. Variable(s) entered on step 1: TAS_DDF. 
 
Logistic regression analysis for TAS_DIF score predicting FND group status (FND 
diagnosis present or absent), controlling for covariates (depressive symptoms, anxiety 
symptoms, and educational attainment) 
 
Block 2: Method = Enter 
 
Omnibus Tests of Model 
Coefficients 
 
Chi-
square df Sig. 
Step 1 Step 1.813 1 .178 
Block 1.813 1 .178 
Model 50.804 4 .000 
 
Variables in the Equation 
 B S.E. Wald df Sig. Exp(B) 
95% C.I.for 
EXP(B) 
Lower Upper 
Step 
1a 
PHQ8_TOT .205 .159 1.656 1 .198 1.227 .898 1.677 
GAD7_TOT -.063 .149 .180 1 .671 .939 .701 1.257 
Highest 
educational 
qualification 
-.744 .254 8.589 1 .003 .475 .289 .782 
TAS_DIF .107 .080 1.778 1 .182 1.113 .951 1.303 
Constant .144 1.696 .007 1 .932 1.155   
a. Variable(s) entered on step 1: TAS_DIF. 
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Logistic regression analysis for TAS_EOT score predicting FND group status (FND 
diagnosis present or absent), controlling for covariates (depressive symptoms, anxiety 
symptoms, and educational attainment) 
 
Block 2: Method = Enter 
 
Omnibus Tests of Model 
Coefficients 
 
Chi-
square df Sig. 
Step 1 Step 3.637 1 .057 
Block 3.637 1 .057 
Model 52.628 4 .000 
 
Variables in the Equation 
 B S.E. Wald df Sig. Exp(B) 
95% C.I.for 
EXP(B) 
Lower Upper 
Step 
1a 
PHQ8_TOT .288 .138 4.345 1 .037 1.333 1.017 1.747 
GAD7_TOT -.077 .136 .324 1 .569 .926 .709 1.208 
Highest 
educational 
qualification 
-.622 .251 6.169 1 .013 .537 .328 .877 
TAS_EOT .194 .108 3.242 1 .072 1.214 .983 1.499 
Constant -
2.786 
2.566 1.179 1 .278 .062 
  
a. Variable(s) entered on step 1: TAS_EOT. 
 
Logistic regression analysis for RFQ_C score predicting FND group status (FND diagnosis 
present or absent), controlling for covariates (depressive symptoms, anxiety symptoms, and 
educational attainment) 
 
Block 2: Method = Enter 
 
Omnibus Tests of Model 
Coefficients 
 
Chi-
square df Sig. 
Step 1 Step .811 1 .368 
Block .811 1 .368 
Model 49.803 4 .000 
 
APPENDIX OF SUPPORTING MATERIAL  169 
 
Variables in the Equation 
 B S.E. Wald df Sig. Exp(B) 
95% C.I.for 
EXP(B) 
Lower Upper 
Step 
1a 
PHQ8_TOT .352 .152 5.340 1 .021 1.422 1.055 1.916 
GAD7_TOT -.087 .145 .357 1 .550 .917 .690 1.218 
Highest 
educational 
qualification 
-.782 .261 8.960 1 .003 .458 .274 .764 
RFQ_C .630 .694 .824 1 .364 1.877 .482 7.312 
Constant .664 1.649 .162 1 .687 1.943   
a. Variable(s) entered on step 1: RFQ_C. 
 
Logistic regression analysis for RFQ_U score predicting FND group status (FND diagnosis 
present or absent), controlling for covariates (depressive symptoms, anxiety symptoms, and 
educational attainment) 
 
Block 2: Method = Enter 
 
Omnibus Tests of Model 
Coefficients 
 
Chi-
square df Sig. 
Step 1 Step .040 1 .841 
Block .040 1 .841 
Model 49.031 4 .000 
 
Variables in the Equation 
 B S.E. Wald df Sig. Exp(B) 
95% C.I.for 
EXP(B) 
Lower Upper 
Step 
1a 
PHQ8_TOT .305 .150 4.160 1 .041 1.357 1.012 1.819 
GAD7_TOT -.095 .144 .436 1 .509 .909 .685 1.206 
Highest 
educational 
qualification 
-.738 .262 7.961 1 .005 .478 .286 .798 
RFQ_U .166 .832 .040 1 .842 1.180 .231 6.031 
Constant 1.328 1.529 .754 1 .385 3.772   
a. Variable(s) entered on step 1: RFQ_U. 
 
 
 
APPENDIX OF SUPPORTING MATERIAL  170 
 
Logistic regression analysis for PHQ15 Checklist score predicting FND group status (FND 
diagnosis present or absent), controlling for covariates (depressive symptoms, anxiety 
symptoms, and educational attainment) 
 
Block 2: Method = Enter 
 
Omnibus Tests of Model 
Coefficients 
 
Chi-
square df Sig. 
Step 1 Step .145 1 .704 
Block .145 1 .704 
Model 49.136 4 .000 
 
Variables in the Equation 
 B S.E. Wald df Sig. Exp(B) 
95% C.I.for 
EXP(B) 
Lower Upper 
Step 
1a 
PHQ8_TOT .277 .173 2.567 1 .109 1.319 .940 1.850 
GAD7_TOT -.083 .146 .322 1 .570 .920 .691 1.226 
Highest educational 
qualification 
-.756 .258 8.607 1 .003 .470 .284 .778 
PHQ15_Checklist_TOT .071 .188 .144 1 .705 1.074 .743 1.552 
Constant 1.257 1.511 .692 1 .406 3.514   
a. Variable(s) entered on step 1: PHQ15_Checklist_TOT. 
 
Logistic regression analysis for Neuro Checklist score predicting FND group status (FND 
diagnosis present or absent), controlling for covariates (depressive symptoms, anxiety 
symptoms, and educational attainment) 
 
 
Block 2: Method = Enter 
 
Omnibus Tests of Model 
Coefficients 
 
Chi-
square df Sig. 
Step 1 Step 5.396 1 .020 
Block 5.396 1 .020 
Model 54.387 4 .000 
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Variables in the Equation 
 B S.E. Wald df Sig. Exp(B) 
95% C.I.for 
EXP(B) 
Lower Upper 
Step 
1a 
PHQ8_TOT .151 .157 .920 1 .337 1.163 .854 1.582 
GAD7_TOT -.110 .153 .516 1 .473 .896 .664 1.209 
Highest 
educational 
qualification 
-.558 .271 4.224 1 .040 .572 .336 .974 
Neuro_TOT .764 .470 2.642 1 .104 2.148 .854 5.398 
Constant .503 1.653 .093 1 .761 1.654   
a. Variable(s) entered on step 1: Neuro_TOT. 
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Appendix 13 
 
Author submission guidelines for the Journal of Psychosomatic Research 
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Appendix 14 
 
Declaration of end of study 
 
DECLARATION OF THE END OF A STUDY 
 
(For all studies except clinical trials of investigational medicinal products) 
 
To be completed in typescript by the Chief Investigator and submitted to the 
Research Ethics Committee (REC) that gave a favourable opinion of the research 
within 90 days of the conclusion of the study or within 15 days of early termination.   
For questions with Yes/No options please indicate answer in bold type. 
 
1. Details of Chief Investigator 
Name: 
Garret Coy 
Address: 
XXXXXXXXXXXXXXXXXXXXXXXXXXXXX 
Telephone: 
XXXXXXXXXXXXXXXXXXXXXXXXXXXXX 
Email: 
XXXXXXXXXXXXXXXXXXXXXXXXXXXXX 
Fax: 
n/a 
 
2. Details of study 
Full title of study: 
Emotional awareness, mentalization and symptom 
complexity in functional neurological symptom 
disorder (FND) 
Research sponsor: 
Prof. Paul Camic, Canterbury Christ Church 
University 
Name of REC: 
East of England REC 
REC reference number: 
17/EE/0191 
 
3. Study duration 
Date study commenced: 
06/08/2017 
Date study ended: 
25/07/2018 
Did this study terminate 
prematurely? 
No 
If yes, please complete sections 4, 5, 6, & 7.  
If no, please go direct to section 8. 
 
4. Recruitment 
Number of participants 
recruited 
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Proposed number of 
participants to be recruited 
at the start of the study 
 
If different, please state 
the reason or this 
 
 
5. Circumstances of early termination 
What is the justification for 
this early termination?  
 
 
6. Temporary halt 
Is this a temporary halt to 
the study? 
Yes / No 
If yes, what is the 
justification for temporarily 
halting the study?  
When do you expect the 
study to re-start? 
e.g. Safety, difficulties recruiting participants, trial has 
not commenced, other reasons. 
 
7. Potential implications for research participants 
Are there any potential 
implications for research 
participants as a result of 
terminating/halting the 
study prematurely?  
Please describe the steps 
taken to address them. 
 
 
8. Final report on the research 
Is a summary of the final 
report on the research 
enclosed with this form? 
Yes 
If no, please forward within 12 months of the end of the 
study. 
 
9. Declaration 
Signature of  
Chief Investigator: 
X 
Print name: 
Garret Coy 
Date of submission: 
27/08/2018 
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Appendix 15 
 
Final study report for REC and study participants 
 
 
Research study final report 
 
Study title: Emotional awareness, mentalization and symptom complexity in functional 
neurological symptom disorder (FND) 
 
What was being studied? 
Previous research with people with functional neurological disorder (FND) has suggested that 
they may have difficulty with identifying and describing emotions (a concept known as 
‘alexithymia’).  Other research has suggested that people who have difficulty understanding 
their own and others’ mental states (a concept known as hypomentalization) may also have 
difficulty with working out which bodily sensations belong to which emotions.  This study 
aimed to investigate if alexithymia and hypomentalization were difficulties for people with 
FND in the UK.   
 
How was this studied? 
A group of service users with FND, and a group of people who did not have FND (referred to 
as control group participants) completed a series of questionnaires.  These questionnaires 
asked participants about how they thought about their emotions, and how they thought about 
their own minds and the minds of others.  There were also questions about current symptoms 
of low mood and anxiety, and about symptoms of different neurological and physical health 
conditions.  In total, 29 people with FND and 41 control participants took part.  The 
questionnaire scores of the two groups were then compared, to explore whether there were 
significant differences between the groups. 
 
What were the results? 
Participants with FND did, on average, report more difficulties with identifying and 
describing emotions (alexithymia), and with understanding their own and others’ mental 
states (hypomentalization), than control group participants.  The participants with FND in 
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this study also, on average, had significantly more symptoms of low mood and anxiety than 
control group participants, as well as significantly fewer years spent in formal education.  
After these differences were factored in to the analyses, people with FND still, on average, 
had significantly higher scores on the alexithymia questionnaire, but the groups were no 
longer significantly different on the hypomentalization questionnaire.   
When the scores of everyone that had taken part in the study were explored further, it 
was found that higher levels of alexithymia and hypomentalization were associated with 
higher numbers of neurological and physical health complaints.  This suggests that 
alexithymia and hypomentalization may contribute to anyone experiencing problems with 
their neurological or physical health, and that this process is not unique to people with FND.  
 
What does this mean for people with FND? 
Difficulties with identifying and describing emotions, and with understanding their own and 
others’ mental states, appear to be common problems for people with FND.  As a result, it 
may be helpful for clinicians working with people with FND to explore these issues with 
service users.  Questionnaires such as those used in this study could help with that 
exploration.  This may help clinicians to think about how best to explain FND to people, and 
how to make sure that they are offering support that the person will find meaningful and 
helpful.   
The findings of this study may also help other researchers and people working with 
people with FND to better understand why people develop FND, and other conditions with 
symptoms like it.  A relatively small number of people took part in this particular study, and 
the participants with FND, on average, differed from the participants without FND in some 
other ways too (such as their current symptoms of low mood and anxiety, and their 
educational histories).  As a result, it is not possible to say that the findings of this study 
apply to all people with FND.  The results do suggest that exploration of the roles of 
alexithymia and hypomentalization in the thinking styles of people with FND may be a 
helpful area to research further in the future.   
 
Thank you for taking part in the study.  Your participation has helped us to 
understand FND a little better.  I hope that you found taking part in the study interesting too. 
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Appendix 16 
Consent procedure for the study 
 
As per the guidance provided in the Canterbury Christ Church University Doctorate in 
Clinical Psychology Guidelines for the preparation of the Major Research Project 
(Assessment Handbook, Appendix 21), and the study protocol that was approved by the East 
of England Research Ethics Committee (REC Reference no. 17/EE/0191), the informed 
consent forms completed by study participants have been stored as follows: 
1) Written consent forms, completed by 23 participants from the functional neurological 
disorders group, were submitted to the University Research Administrator in a sealed 
envelope for storage by the University, on 27th April, 2018. 
2) Consent forms for the remaining 6 participants from the functional neurological 
disorders group, and from all 42 participants of the healthy control group, were 
obtained electronically via the University-approved Qualtrics online survey website.  
The University Research Director, Prof Paul Camic, was emailed on 26th April 2018, 
as per the University guidelines, to confirm that this was the reason why written 
consent forms were not being submitted for 48 study participants. 
 
 
 
 
 
 
 
 
